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ABSTRACT 
A leading cause of mortality in diffuse large B-cell lymphoma (DLBCL) patients is the 
development of resistance to the CHOP regimen, the anthracycline-based chemotherapy 
consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone. Our first objective of 
this work was to investigate the impact of Nuclear factor erythroid–related factor 2 (Nrf2)/ 
glucose-6-phosphate dehydrogenase (G6PDH) pathway on CHOP-resistance in DLBCL cell 
lines. We provide evidence here that a Nrf2/G6PDH pathway plays a role in mediating CHOP 
resistance in DLBCL. We found that CHOP-resistant DLBCL cells expressed both higher Nrf2 
and G6PDH activities and lower reactive oxygen (predominantly superoxide) levels than CHOP-
sensitive cells. We hypothesized that increased activity of the Nrf2/G6PDH pathway leads to 
higher GSH production, a more reduced state (lower ROS), and CHOP-resistance. In support of 
our hypothesis, direct inhibition of G6PDH or knockdown of Nrf2/G6PDH lowered both 
NADPH and GSH levels, increased ROS, and reduced tolerance or CHOP-resistant cells to 
CHOP. We also present evidence that repeated cycles of CHOP treatment select for a small 
population of Nrf2High/G6PDHHigh/ROSLow cells that are more tolerant of CHOP and might be 
responsible for the emergence of chemoresistant tumors. We propose that sensitive Nrf2Low 
/G6PDHLow /ROSHigh cells are essentially killed off by CHOP allowing for the selective 
propagation of the small population of CHOP-resistant Nrf2High/G6PDHHigh/ROSLow cells, 
thereby resulting in relapse of lymphoma. 
Our second objective was to study rifamycins’ potency at sensitizing drug resistant cancer cells 
to chemotherapeutics. We have discovered a novel chemosensitizer (RTI-79, a rifamycin-
derivative) with a broad spectrum of action that includes ovarian cancer and double and triple hit 
non-Hodgkin’s lymphoma. RTI-79 is relatively non-toxic and has favorable in vivo safety and 
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pharmacokinetic (PK) profiles. RTI-79 in combination therapies is effective in multiple drug 
resistant cancers in mouse models. RTI-79 works by dramatically increasing intracellular 
reactive oxygen species (ROS), primarily superoxide, through redox cycling. The level of ROS 
induction is directly correlated with drug sensitivity. Importantly, RTI-79 also triggers the 
unfolded protein response (UPR) that results in increased ubiquitination and loss of Nrf2, the 
primary sensor for intracellular ROS. Thus, RTI-79 both increases ROS and squelches Nrf2’s 
ability to respond to ROS. This unique mechanism provides a broad and novel approach for the 
very safe application of RTI-79, and other rifamycins, in treating drug resistant cancers. 
We also showed that RTI-79 acts to increase the oxidative state in chemoresistant cancer cells by 
inducing superoxide (O2-) and downregulating the Nrf2/G6PDH/NADPH/GSH pathway. RTI-79 
also increased the ubiquitination state of several mitochondrial chaperone proteins (mtDnaJ 
[HSP40]), HSP60, HSP70mt [mortalin]) and decreased activated CREB, which are known to 
play roles in mitochondrial unfolded protein response (UPRmt) retrograde signaling. 
In summary, this research explores a new way to overcome the chemoresistance particularly in 
DLBCL and ovarian carcinoma. The new findings of this study will significantly impact our 
understanding of the role of Nrf2/G6PDH signaling pathway in DLBCL, and provide hope for 
the development of rational therapies for both newly diagnosed patients with DLBCL and also 
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GENERAL INTRODUCTION AND LITERATURE REVIEW: 
NON-HODGKIN’S B CELL LYMPHOMA: ADVANCES IN MOLECULAR STRATEGIES 
TARGETING DRUG RESISTANCE 
* 1
1.1 Introduction  
1.1.1 The problem of multidrug resistance in non-Hodgkins lymphoma 
Non-Hodgkins lymphoma (NHL) is a heterogeneous class of cancers displaying a diverse range 
of biological phenotypes, clinical behaviors, and prognoses. The majority of NHL cases 
originate from B cells with about 10% arising from T cells (1, 2). B cells that normally undergo 
clonal expansions at different stages of differentiation can give rise to the B cell type of NHL 
(3).The standard treatment for NHL is the anthracycline-based chemotherapy regimen, termed 
CHOP, which is composed of cyclophosphamide, doxorubicin, vincristine, and prednisolone (4). 
The addition of rituximab (monoclonal antibody to CD20) to CHOP (R-CHOP) has provided the 
first major improvement in therapy in over three decades and is now the new standard for 
treatment (5). Most NHL patients initially respond to chemotherapy yielding complete response 
rates of 40–50% (6-10). Regrettably, a substantial population of patients undergo relapse, 
resulting in disappointing 3-year overall survival rates of only about 30% (11). The problem is 
compounded by the higher doses of CHOP administered to relapsed patients, which have 
resulted in severe side-effects and a response in only about one-third of relapsed patients (12-
14). Relapsed lymphomas are not only refractory to subsequent treatments with the initial 
chemotherapy regimen but also can exhibit cross-resistance to a wide variety of anticancer drugs. 
*
Reprinted with permission from “Non-Hodgkin's B-cell lymphoma: advances in molecular
strategies targeting drug resistance.” by Maxwell SA, Mousavi-Fard S, 2013. Exp Biol Med
(Maywood). 238(9):971-90, Copyright 2013 by SAGE Publishing.
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Acquisition of chemoresistance in B cell lymphomas is due to the emergence of subpopulations 
of drug-resistant tumor cells, which leads to the failure of standard CHOP therapies. 
Chemoresistance in NHL is not consistently associated with the upregulation of multidrug pump 
(i.e. P-glycoprotein; MDR1) expression indicating the existence of other drug-resistant 
mechanisms (15, 16). Inherent genetic heterogeneity and instability of the tumor cells drive the 
acquisition of drug resistance in lymphoma (17). It is now apparent that a new generation of less 
toxic and more targeted approaches based on rational drug design is needed to prevent and/or 
reverse chemoresistant disease (18). The purpose of this article is to highlight the many new 
insights into the molecular basis of chemorefractory NHL, which are leading the way to the 
rational design of novel drugs to overcome chemoresistance. Due to the genetic heterogeneity of 
B-cell NHL, many different pathways leading to drug resistance have been identified. Successful 
treatment of chemoresistant NHL will thus require cocktails of combinatorial drugs targeting 
multiple pathways specific to different subtypes of NHL as well as the development of 
personalized approaches to address patient-to-patient genetic heterogeneity. 
 
1.1.2 Innate and acquired drug resistance varies among subtypes of NHL  
Aggressive NHL includes diffuse large B cell lymphoma (DLBCL), mantle-cell lymphoma 
(MCL), Burkitt’s lymphoma (BL), follicular lymphoma (FL) and peripheral T-cell lymphoma 
(PTCL). Each of these subtypes of NHL display a wide range of responses and outcomes to 
standard chemotherapeutic regimens due to genetic heterogeneities. Despite remarkable 
advances in chemotherapy, more than half of patients with aggressive B cell NHL (B-NHL) are 
incurable (6). PTCL, in particular, remains a challenge for chemotherapy since there are no 
drugs that can prevent progression of the disease (19). The two most common types of NHL are 
DLBCL and FL, representing more than half of all patients with B-NHL (1). The most common 
3 
 
histological type is DLBCL and is classified as an aggressive subtype, but potentially is curable 
with chemotherapy (1, 20-22). The second most frequent type of NHL is FL, which is usually 
incurable with conventional chemotherapy, and exhibits a median survival of 10 years 
postdiagnosis (23). MCL is an aggressive disease with a 3–4-year median survival and poor 
responsiveness to conventional chemotherapy (24-27). 
 
1.1.3 Drug-resistant DLBCL  
Most DLBCL patients initially respond favorably to CHOP, but 50% eventually relapse with 
CHOP-resistant disease that disseminates and is highly lethal without transplantation (28). Even 
though CHOP-resistant DLBCL affects about 10,000 new cases in USA each year, the molecular 
features of CHOP-resistant DLBCL have not been adequately defined. Drug resistance can be 
inherent (innate) from the beginning (29) or develop from prior exposure to chemotherapy 
(acquired) (30, 31). The varied responses of DLBCL to chemotherapy are due to aberrations in 
multiple molecular pathways, which are attributed to the heterogeneous genetic nature of 
DLBCL (32). Gene expression profiling (GEP) of patient tumors has better defined the 
molecular heterogeneity underlying the heterogeneous clinical behavior of DLBCL. Patients 
with DLBCL have been classified into three groups according to their GEP patterns based on the 
three cell-of-origin signatures, activated B cell–like DLBCL (ABC-DLBCL), germinal-center B 
cell–like DLBCL (GCB–DLBCL) and mediastinal (33-36). The GCB and ABC subcategories 
are characterized by distinct differences in survival, chemoresponsiveness and dependence on 
signaling pathways (37). ABC–DLBCL resembles in vitro activated B cells. In a separate 
multiple clustering array analysis (38), DLBCLs were categorized into Ox-phos, 
BCR/proliferation and host-response signatures. The BCR/proliferation subset displayed the 




1.1.4 Mantle-cell lymphoma  
Mantle-cell lymphoma (MCL) is an aggressive disease that has a poor response to conventional 
chemotherapy resulting in an overall survival of about 3–4 years (27, 39). A major problem in 
treating MCL is the occurrence of relapse caused by resistance to chemotherapy. Many different 
drug combinations comprised of alkylating agents, anthracyclines and purine analogs have been 
tested in MCL patients (40). One of the unique features of MCL is a cluster differentiation (CD) 
phenotype associated with a specific chromosomal translocation, t(11;14)(q13;q32), which 
translocates the cyclin D1 gene to be under the control of the immunoglobulin heavy chain gene 
enhancer, resulting in upregulation of cyclin D1 (41). Overexpression of cyclin D1 plays a 
critical role in the pathogenesis and chemorefractoriness of MCL. However, accumulating 
evidence indicates that MCL frequently is dysregulated not only in cell-cycle regulation but also 
in apoptosis and DNA repair (42, 43). MCL frequently can also be innately resistant to 
anticancer agents (43). A number of dysfunctional biochemical pathways have been identified 
that may contribute to the relatively high resistance of MCL to chemotherapy-induced apoptosis 
(44), including the activation of NFκB pathway (45-47), overexpression of antiapoptotic proteins 
and the absence of proapoptotic proteins (48). GEP has also identified the upregulation of genes 
associated with multidrug resistance in MCL (49). The resistance of MCL to alkylating agents 
and to anthracycline can also result from the upregulation of the glutathione S-transferase (GST) 
gene, which is located in 11q13 and thus co-amplified along with the cyclin D1 gene (50) as well 
as the phosphoinositide 3-kinase/Akt pathway (PI3K/Akt) (51, 52). Despite the generation of 
several new therapeutic agents directed against PI3K/Akt, B cell receptor signaling and Bcl-2, 





1.2 Drug-resistance pathways in B-cell NHL  
1.2.1 PI3K/Akt pathway in B cell NHL drug resistance  
The PI3K/Akt pathway plays a central role in promoting survival and chemoresistance in NHL 
(54-58). Dysregulation of the PI3K/Akt pathway is frequent in DLBCL and worsens prognosis 
(58-65). New drugs targeting this pathway have shown encouraging results in treating relapsed 
NHL patients (66-71). However, not all chemorefractory DLBCL patients show positive 
responses to current Akt pathway inhibitors, and many experience severe side-effects (72, 73). A 
primary mediator of PI3K signaling is the Akt/protein kinase B kinase, which acts to promote 
cell survival through direct phosphorylation of apoptotic regulators. Akt phosphorylation of 
proapoptotic substrates (including Bad, FOXO, GSK-3b and ASK1) targets them for binding to 
14-3-3 proteins (74-80), which effectively neutralizes their ability to induce apoptosis. A role for 
the activation of the Akt pathway in promoting chemoresistance in NHL was shown by treatment 
with pharmacological inhibitor (LY-294002) and by Akt siRNA, both of which inhibited Bcl-xL 
expression and sensitized the cells to chemotherapeutics (81). Moreover, higher Akt activity was 
observed in CHOP-resistant DLBCL cells than in CHOP-sensitive cells, which was associated 
with the upregulation of 14-3-3zeta (82, 83). Chemical inhibition of Akt (82) or shRNA-
mediated knockdown of 14-3-3zeta (83) restored CHOP sensitivity to the resistant cells, 
indicating that CHOP resistance was mediated by these proteins, was reversible and might be 
targeted as a clinical strategy for CHOP resensitization. mTOR in the Akt pathway is an 
important therapeutic target for DLBCL. Rapamycin inhibited mTORC1 in DLBCL lines and 
primary tumors with minimal cytotoxicity (84). Clinical trials of the rapamycin analogs, 
temsirolimus and everolimus have demonstrated overall response rates of about 30% for relapsed 
DLBCL (85-87). However, only about half of relapsed patients respond to mTOR inhibitors. A 
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critical focus needs to be on the development of new inhibitors of the PI3K/Akt pathway that 
bypass resistance mechanisms. As an example, addition of a histone deacetylase inhibitor 
reversed resistance to rapamycin (84). 
 
1.2.2 Dysregulated apoptotic pathways 
The germinal center (GC) is the location of immune surveillance in the lymph node. B cells that 
express functional B cell receptors and have a block to execution of an activated apoptotic 
program migrate to the GC (88). One hallmark of germinal center-derived B cell NHL (GC-
DLBCL) is resistance to apoptosis characterized by the dysregulation of apoptotic control 
mechanisms (37, 89, 90). In addition, dysregulation of genes involved in apoptotic pathways has 
also been reported to be associated with chemoresistance in activated B cell-like DLBCL (ABC-
DLBCL). Thus, a promising approach in both frontline and salvage therapeutic strategies in B 
cell NHL is targeting altered apoptotic pathways. Strategies targeting the two main apoptotic 
pathways, extrinsic and intrinsic, are summarized below.  
 
1.2.2.1 Extrinsic (death receptor) pathway  
The tumor-necrosis factor receptor (TNFR) family of transmembrane proteins, including the 
death receptors for Fas (CD95) and tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL), induces cell death. TRAIL mediates apoptosis by binding to cell-surface 
transmembrane receptors, either death receptor 4 (DR4/APO2/TRAIL-R1) or death receptor 5 
(DR5/KILLER/TRAIL-R2/TRICK2) (91), which recruit the death-inducing signaling complex 
composed of FADD and the inactive proenzymatic form of the apoptosis-initiating proteases 
caspase-8 (92, 93). Self-activation of caspase-8 by autoproteolysis leads to the activation of the 
executioner caspase-3 to carry out apoptosis. TNFR family members can selectively induce 
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apoptosis in some drug-resistant B cell lymphomas (94-97). Twelve out of 22 primary 
lymphoma cell cultures derived from biopsied DLBCL samples were sensitive to TRAIL, (97) 
which included seven clinically chemoresistant lymphomas. TRAIL was found to induce 
apoptosis in DLBCL cells expressing the upregulation of prosurvival molecules, Bcl- 2 and/or 
X-linked inhibitor of apoptosis (XIAP). Thus, TRAIL might be an effective therapy for drug-
resistant DLBCL patients that show dysregulated extrinsic apoptosis pathways (96, 98, 99). The 
Bfl-1 protein is required for the survival of malignant B cells and might be a potential target 
against drug resistant B cell lymphoma (100). Bfl-1 is a direct transcriptional target of nuclear 
factor-kappa B (NF-kB) (101-103), and its upregulation is associated with an increased 
resistance to tumor-necrosis factor (TNF)-α, anti-CD95, TRAIL and chemotherapeutic drugs 
(102-104). In DLBCL, downregulation of Bfl-1 occurs in tumor cells induced to undergo 
apoptosis by inhibition of the activated NF-kB pathway (105). Moreover, short-hairpin RNA 
silencing of Bfl-1 in DLBCL cell lines sensitized those cell lines to anti-CD20 (rituximab) - 
mediated cell death and chemotherapeutic agents. Thus, Bfl-1 will be a candidate target in the 
design of new strategies for drug-resistant cancer therapy. 
 
1.2.2.2 Intrinsic pathway  
The Bcl-2 family regulates an apoptotic pathway that is initialized at the mitochondrion known 
as the intrinsic apoptotic pathway. Bcl-2 family members function through mutual interactions 
with each other and the balance between the anti-apoptotic (Bcl-2, Bcl-xL, Mcl-1) and the 
proapoptotic (Bax, Bak; and the BH3-only Bid, Bim and PUMA protein) members are critical 
for preventing or initiating apoptosis (106, 107). The BH3-only proapoptotic (Bid, Bim, PUMA) 
proteins act as molecular sensors of cellular stress or damage and are activated in response to 
DNA damage, growth factor withdrawal and oncogene activation (108). Many chemotherapeutic 
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drugs activate the intrinsic apoptosis pathway, leading to the release of proapoptotic molecules, 
including cytochrome c, from the intermembrane space of mitochondria into the cytosol. 
Cytochrome c, Apaf-1 and procaspase-9 complex together to form the apoptosome machinery in 
the cytoplasm. The apoptosome promotes oligomerization of Apaf-1, which then triggers the 
activation of the initiator procaspase-9. The active caspase-9, in turn, cleaves and activates 
downstream executioner caspases, including pro-caspase-3, which cleaves proteins, thus 
producing the characteristic apoptotic phenotype of blebbing, nuclear condensation and cell 
shrinkage. Dysregulation of apoptosome formation and caspase activation has been associated 
with chemoresistance in B cell lymphoma. BL cells commonly are resistant to apoptosis 
induction by chemotherapeutic agents, which has been attributed to deficient levels of Apaf-1, 
thus leading to the failure of cytochrome c to promote apoptosome formation and caspase 
activation (109). Overexpression of antiapoptotic family members in B cell lymphomas is 
associated with the inhibition of apoptosis and chemotherapy resistance, resulting in lower 
clinical response rates and shortened survival (110-114). Bcl-2 was observed overexpressed in 
about 80% of FL and 20% of DLBCL as a result of the t (14; 18) translocation and amplification 
of the Bcl-2 gene, respectively (115-117). Bcl-2 expression was also correlated with a higher 
relapse-rate, shorter disease-free survival and shorter overall survival (16, 118-121). Antisense-
mediated repression of Bcl-2 expression resulted in significant increases in the sensitivity of 
lymphoma cells to chemotherapeutic drugs (122-124). Oblimersen (Genta Inc.) is a 
phosphorothioate Bcl-2 antisense oligonucleotide, which in combination with rituximab, resulted 
in an overall response rate of 42% including 10 complete responses and 8 partial responses in 
relapsed B cell NHL patients (125). Median duration of response was 12 months with minimal 
toxicities. Thus, co-administration of Oblimersen and rituximab is a safe treatment that will be 




1.2.3 IAP proteins  
Inhibitor of apoptosis (IAP) proteins can block executioner caspases (126). Overexpression of 
IAPs (XIAP) has been shown to result in resistance to agents that induce apoptosis pathways 
(127, 128). XIAP is the most potent inhibitor of the apoptosis cascade and can repress apoptosis 
induced by TNF, TRAIL, Fas-L and conventional chemotherapeutics (127, 128). In DLBCL, 
XIAP expression was associated with a poor prognosis (129). A small-molecule XIAP 
antagonist re-activated the intrinsic apoptosis pathway in drug-resistant DLBCL cell lines (130, 
131).Peripheral blood mononuclear cells and tonsil germinal-center B cells from healthy donors 
were not affected, validating the XIAP antagonist for possible development as a therapy for 
chemotherapy-refractory DLBCL. The sensitivity of DLBCL cells to the XIAP antagonist could 
be predicted from molecular markers, such as expression of XIAP, Bcl-2 and levels of 
constitutive caspase-9 activation (131), indicating a potential for selecting patients for XIAP 
therapy. 
 
1.2.4 DNA damage response  
Mutations in the DNA damage response (DDR) genes may promote tumor formation as well as 
drive emergence of drug resistance. The Atm gene product is a primary component of the DDR, 
which has a phosphatidylinositol-3- kinase-like protein kinase that phosphorylates many proteins 
upon DNA damage (132). Atm mutations have identified in hematologic malignancies. An 
association between Myc activation and Atm inactivation has been identified during the 
progression of human B cell lymphomas (133). In mice, Atm loss collaborated with Myc 
activation to accelerate the development of lymphomas (134-136). Following anticancer therapy, 
Atm (DDR)-compromised lymphomas exhibited defects in ability to undergo apoptosis and had 
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a poorer long-term outcome as compared to DDR-competent lymphomas. Atm thus appears to 
prevent tumor progression by converting oncogenic signaling into apoptosis, resulting in 
selection against an Atm-dependent DDR and the emergence of drug-resistant lymphomas 
 
1.2.5 NFκB pathway  
Activation of NF-kB is a driver in apoptosis resistance in a variety of B cell malignancies 
leading to poor outcome in lymphoma patients (137, 138). The NF-kB family has the capacity to 
regulate transcription of a diverse array of genes involved in cancer cell growth, including those 
involved in proliferation and resistance to apoptosis (139-142). Drug-resistant lymphoma cell 
lines have been sensitized by treatment with inhibitors of the NF-kB pathway (143, 144). Bfl-1 is 
a direct transcriptional target of NF-kB (101-103), and its upregulation is associated with 
decreased sensitivity in lymphomas to chemotherapeutic drugs and apoptotic stimuli, including 
TNF-α and anti-CD95 (102-104). Inhibition of NF-kB pathway in DLBCL (37, 105) led to the 
downregulation of Bfl-1 expression and apoptosis. Knockdown of Bfl-1 in sensitized DLBCL 
cell lines to anti-CD20 (rituximab) and standard chemotherapeutics (100). 
 
1.2.6 microRNAs  
A microRNA, miR-21, has been shown to influence sensitivity of DLBCL cells to CHOP by 
impacting the PI3K/Akt signaling pathway (145). Mir21 targets PTEN for downregulation and 
NFκB upregulates miR-21. Knockdown of NFκB decreased miR-21 and sensitized DLBCL cells 
to chemotherapy. A frequent genetic alteration that has been observed in MCL is chromosome 
13q31–q32 amplification targeting a microRNA cluster termed miR-17–92 (146-
148).Upregulation of miR-17–92 activated the PI3K/AKT pathway and inhibited apoptosis 
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induced by chemotherapeutics in MCL cell lines (149). Downregulation of miR-17–92 repressed 
the PI3K/Akt pathway and inhibited tumor growth in a xenograft MCL mouse model. 
 
1.2.7 TGF-β pathway  
Members of the transforming growth factor-b (TGF-β superfamily modulate proliferation, 
apoptosis and differentiation in many different cell types. TGF-β inhibits cell proliferation by 
arresting cells in the G1 phase of the cell cycle through the p15INK4b, p21Cip1/WAF1, p27 and 
c-Myc proteins (70). Binding of TGF-β receptors to their ligands activates the serine/threonine 
kinase activity of the TGF-β receptors (TbRI and TbRII). The ligand-activated TbRII 
phosphorylates and activates the TbRI, which in turn transmits the TGF-β signal by 
phosphorylating and activating the Smad2 and Smad3 proteins. The activated Smads oligomerize 
with Smad4, and the complexes then translocate to the nucleus where they regulate transcription 
of TGF-β target genes (66, 67, 150). Lymphoma cells can acquire resistance to TGF-β through 
promoter methylation of the TbRII gene (71). Promoter analysis in lymphomas revealed CpG 
methylations at 25 and 140 of the TRII promoter that correlated with the silencing of the TRII 
gene. Overexpression of BCL6 contributes to TGF-β resistance in B-cell lymphoma. BCL6 
transcriptionally represses Smad4 (72). B cell lymphoma cells with upregulated BCL6 were 
refractory to TGF-β, whereas knockdown of BCL6 expression restored the response to TGF-β.  
 
1.2.8 Oxidative stress pathways  
Changes in oxidative stress pathways may explain the more aggressive tumor phenotype of drug-
resistant lymphoma variants. In a murine lymphoma model, lymphoma cells transfected with 
catalase or selected for resistance to hydrogen peroxide were resistant to CHOP (151-153). 
Oxidative stress-resistant cells demonstrated an altered metabolic profile, including the ability to 
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generate ATP from alternative carbon sources such as glutamine (154, 155). When treated with 
glucocorticoids, the oxidative stress-resistant cells were better able to maintain ATP levels as 
compared to sensitive parental cells (155). Experiments with an uncoupler of mitochondrial 
respiration showed that the oxidative stress-resistant cells produced more ATP from 
mitochondria than the sensitive cells (154). 
 
1.2.9 Reactive oxygen species  
Once inside the cell, anthracyclines in the CHOP cocktail kill lymphoma cells by DNA 
intercalation, topoisomerase II inhibition and reactive oxygen species (ROS) induction. The type 
of ROS generated can be critical; superoxide anion and hydrogen peroxide inhibited cancer cell 
migration and invasion, whereas hydroxyl radical promoted cell migration and invasion (156). 
The Akt-survival pathway has been implicated in regulating ROS in lymphoma cells. Akt 
activation correlated with both decreased ROS and increased cell survival in lymphoma cells 
(157). Chronic ROS exposure can generate lymphoma cells with upregulated antioxidant defense 
systems, which results in chemoresistance (158). Oxidative stress-resistant variants expressed 
increased catalase and superoxide dismutase activities and increased phase 2 enzymes, 
NAD(P)H: quinone oxidoreductase and GST µ and π. 
 
1.2.10 Proton pumps  
The acidity of the tumor microenvironment due to hypoxic conditions, which influence ROS 
production, plays an important role in tumor progression, chemoresistance and metastatic 
behavior (159, 160). Cancers adjust to acidity by upregulating proton extrusion activity, thus 
allowing the tumor cells to survive (161-163). Tumor cells control intracellular pH through 
proton pumps like the vacuolar-type H + ATPase (V-ATPase). Modification of cellular pH 
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gradients by treatment with proton pump inhibitors (PPIs) sensitized B-lymphoma cells to 
chemotherapeutics through ROS production (164). Neutralization of ROS by the antioxidant, N-
acetylcysteine, delayed apoptosis. PPIs also inhibited the growth of B-cell lymphoma in SCID 
mice. Thus, PPIs may provide for therapeutic approaches for drug-resistant B cell lymphomas. 
 
1.2.11 GSH 
The glutathione-S-transferases (GSTs) multigene family of enzymes detoxify electrophilic 
xenobiotics, including alkylating agents, and reduce oxidative stress (165-171). Overexpression 
of the GST-π isoenzyme has been associated with alkylating agent and anthracycline resistance 
in lymphomas (171). 
 
1.2.12 CD antigens  
1.2.12.1 CD20-rituximab  
The coadministration of rituximab to CHOP chemotherapy has significantly increased the 
survival of DLBCL patients (172-179). Rituximab is a humanized monoclonal antibody that 
binds to the CD20 antigen on B lymphocytes (180). CD20 is expressed by >99% of B-cell NHL 
(2), which is not internalized following antibody binding (181) or secreted into the circulation 
(182). However, given that it is also expressed by normally differentiated pre-B cells and B cells 
(183, 184), normal B cells are also depleted during rituximab therapy, so that NHL patients have 
a prolonged B-lymphopenia following rituximab therapy (185). Regrettably, many patients will 
relapse after rituximab/ CHOP (R-CHOP) therapies (184, 186-193). Rituximab exerts its anti-
lymphoma activity through multiple mechanisms, including growth inhibition, apoptosis, 
complement-dependent cell cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity 
(ADCC) (60, 184). Although rituximab mediates CDC and ADCC of CD20- positive human B 
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cells (194), it can have direct apoptotic effects. Unfortunately, resistance to rituximab can 
eventually evolve in some patients during the course of the disease, which is only explained in 
part by the loss of CD20 expression (195). 
A variety of signaling events have been observed in lymphoma cells exposed to rituximab in 
vitro, including the activation of Src-family of protein tyrosine kinases, decreased NFκB activity 
and downregulation of Bcl-2 levels (196-201). Rituximab inhibited Akt in B cell lymphoma cell 
lines, which contributed to the sensitization of drug resistant cells to chemotherapeutic drugs 
(81). B-lymphoma cell lines resistant to rituximab have cross-resistance to multiple 
chemotherapeutic agents and exhibit downregulation of the Bcl-2 family proteins Bax and Bak 
(202). Repeated exposure to rituximab generates a therapy resistant phenotype by modulating the 
expression of Bax and Bak. The development of new inhibitors of the Akt and Bcl-2 pathways 
will now allow rationally designed clinical trials addressing Rituximab resistance that employ 
combinations of the new inhibitors and rituximab. 
 
1.2.12.2 CD147  
Upregulation of extracellular matrix metalloproteinase inducer (EMMPRIN or CD147) drives 
lymphoma progression and induces resistance to chemotherapeutic drugs (203-208). CD147 is a 
transmembrane glycoprotein of the immunoglobulin superfamily that is expressed on the surface 
of lymphoma cells. It functions as a regulator of matrix metalloproteinase (MMPs) expression in 
the local lymphoma environment (204). High expression of MMPs has been correlated with 
tumor metastasis (209). Reduced CD147 expression led to reduced metastasis and sensitized 





1.2.13 MDR proteins  
The ability of cancer cells to resist the cytotoxic effects of chemotherapeutic agents is termed 
multidrug resistance (MDR), which is manifested by a decreased sensitivity to a wide range of 
nonhomologous drugs targeting multiple diverse pathways (211). Overexpression of the 170–
180 kDa ATP-dependent pump, P-glycoprotein (P-gp transporter), is frequently associated with 
resistance against a wide range of chemotherapeutics (212-215) and results in the MDR 
phenotype. P-gp transports or effluxes chemotherapeutics out of the cell, which reduces the 
intracellular concentration of the drugs, thus protecting cellular structures from damage and 
promoting cell survival. MDR due to the upregulated expression of P-gp product has been 
implicated as a critical factor in the prognosis and clinical outcome of refractory lymphoma 
patients (215-218). Expression of P-gp has been found in all histological types of NHL (219). 
Clinical trials combining chemotherapy with resistance modifiers have provided evidence for the 
role for P-gp in drug resistance in NHL (220-222). However, some reports have indicated a lack 
of correlation between clinical response and P-gp expression (29, 216, 223-225), possibly 
because MDR is mainly implicated in acquired drug resistance in lymphomas (226, 227). Thus, 
upregulation of P-gp is not consistently associated with chemoresistance in NHL, indicating the 
existence of additional drug-resistant pathways and mechanisms (15, 16). 
Upregulation of the PI3K/Akt pathway can influence MDR in lymphoma. PI3K/Akt inhibition 
correlates with downregulation of NFκB activity and reduced P-gp function (228). PI3K/Akt 
activity was higher in drug-resistant lymphoma cell lines than in sensitive cells, and PI3K/Akt 
inhibitors inhibited P-gp function and increased sensitivity to chemotherapeutics in drug-
resistant cell lines. Upregulation of the adenosine triphosphate-binding cassette drug transporter, 
ABCG2, in DLBCL correlated inversely with the disease-free survival (229). Activated 
hedgehog (Hh) signaling stimulated high-ABCG2 expression in DLBCL through direct 
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upregulation of ABCG2 gene transcription (230). Activation of Hh signaling in DLBCL cell 
lines led to co-upregulation of Bcl-2 and ABCG2, which was associated with increased 
resistance to chemotherapeutics. In addition to P-gp, the lung-resistance protein (LRP) is 
associated with MDR in lymphoma. LRP was first identified in a non-P-gp-multidrug-resistant 
lung cancer cell line (231). LRP is the major protein component of vaults, which are complex 
ribonucleoprotein particles located primarily in the cytosol and nuclear membrane and mediate 
nucleocytoplasmic transport (232, 233). Upregulation of LRP is associated with resistance to 
multiple chemotherapeutics (234, 235). High LRP expression was associated with more 
aggressive lymphomas and a lower response rate to chemotherapy than LRP-negative patients 
(236). 
 
1.2.14 Drug metabolizing pathways  
GSTs detoxify electrophilic chemotherapeutics, such as alkylating agents (166-171). GSTs act 
by promoting direct binding of drugs to alkylating agents and steroids and can also neutralize 
free radicals generated by anthracyclines (237-239). Drug resistance in lymphoma has been 
associated with an increase in glutathione content or GST activity (240-242). The GST-π 
isozyme is elevated in lymphoma cell lines resistant to anticancer agents (170). GST- π 
expression has been reported to have prognostic significance in DLBCL (243).  
Glutathione S-transferase P1-1 (GSTP1-1) is a phase II detoxifying enzyme and plays a role in 
resistance to chemotherapeutics. GSTP1-1 may be a prognostic factor in late stage NHL (243, 
244), since survival times were 64 and 25 months for the low and high GSTP1-1 groups, 
respectively. One strategy to overcome drug resistance would consist of treating relapsed NHL 




1.2.15 MAP kinase pathway  
The MAP kinase signaling pathway may influence the sensitivity of B-lymphoma cells to 
chemotherapeutics. The contribution of the MAP kinase pathway and mitochondrial apoptotic 
pathways was studied in a panel of human B lymphoma cell lines exhibiting varying degrees of 
drug resistance and Bcl-2/Bax expression (245). Mitochondrial dysfunction was induced in these 
cells by the mitochondrial toxicants, carbonyl cyanide m-chlorophenylhydrazone (mClCCP) and 
antimycin A. The drug-resistant lines had higher Bcl-2/Bax expression ratios and were less 
sensitive to mitochondrial toxicant-induced apoptosis than the sensitive cell lines. Treatment 
with mitochondrial toxicants led to the activation of the MAP kinase pathway in only the drug-
sensitive lines. Specific inhibition of the MAP kinase pathway augmented baseline and 
mClCCP-induced apoptosis, indicating that differential sensitivity to mitochondrial toxicants in 
B lymphoma cells involved regulation by MAP kinases. 
 
1.2.16 Tyrosine protein kinases  
Oncogenic tyrosine kinases regulate multiple signaling pathways involved in both cell survival 
and resistance to chemotherapeutics (246-252). Binding of antigen to the B-cell receptor (BCR) 
activates phosphorylation of Src family kinases (SFK), which is followed by the activation of 
MAP kinase, PI3kinase and NFκB pathways (253) resulting in B cell activation and survival 
(254, 255).  
Over one-third of DLBCL patients tested expressed active SFKs in their tumors and thus may be 
candidates for treatment with the SFK inhibitor, dasatinib (256). Dasatinib is dual-kinase 
inhibitor that is currently approved for use in chronic myelogenous leukemia (257). In DLBCL 
cell lines, sensitivity to dasatinib varied by 400-fold, and resistance to dasatinib was associated 
with the dysregulation downstream of BCR activation.  
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The anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in glucocorticoid-
resistance in lymphomas (258). The glucocorticoids, prednisolone, and dexamethasone induce 
cell-cycle arrest and apoptosis in lymphoid cells and are included in chemotherapeutic regimens 
for lymphomas (259, 260). Unfortunately, glucocorticoid resistance commonly occurs in 
lymphomas (261-264). In about two-thirds of anaplastic large-cell lymphoma (ALCL), a rare 
type of NHL, a fusion of the nucleophosmin and ALK genes by the t(2;5) chromosomal 
translocation, gives rise to a hybrid NPM–ALK protein (265). Dysregulation of ALK caused by 
fusion to NPM is a causative factor in both ALCL and DLBCL (266-270). Abnormal activation 
of ALK is the result of the fusion of the N-terminal NPM partner encoding an oligomerization 
motif to activate the kinase domain of the ALK protein, which is critical for resistance to 
glucocorticoids (271-273). 
 
1.2.17 p53 tumor suppressor gene  
p53 mutations are often associated with decreased sensitivity to chemotherapeutics (274, 275), 
more aggressive clinical course (276) and higher relapse (16, 277-280). Lymphomas with a p53 
mutation were more likely to be drug-resistant than those with normal p53 and to have a shorter 
progression-free survival (16). 
The BH3-only genes, Puma and Noxa, are direct transcriptional targets of p53. The 
combinatorial action of the p53 target genes, Puma and Noxa, is important for the induction of 
apoptosis by chemotherapeutics in lymphoma cells (281). In nontransformed lymphoid cells, the 






1.2.18 Proteasome  
The 26S proteasome complex is a large multisubunit catalytic complex that degrades ubiquitinated 
proteins (282). Proteasome inhibition has emerged as a new therapeutic option in lymphoma (283). 
The pharmacological proteasome inhibitor (PI), bortezomib (PS-341, Velcade) has shown efficacy 
against NHL through disrupting the equilibrium between protein biosynthesis and degradation 
(282, 284-286). Preclinical studies have demonstrated that proteasome inhibition potentiates the 
activity of other chemotherapeutics (287, 288). However, not all lymphomas are bortezomib 
sensitive, and acquired resistance to bortezomib can occur (284). Although bortezomib has single-
agent efficacy in patients with relapsed or refractory MCL (289-292), about 40–50% of patients 
develop bortezomib-resistant disease. Bortezomib-resistant lymphoma cell lines exhibited residual 
proteasome activity in the presence of bortezomib (293), possibly due to increased expression of 
the b5, b2 and b1/b5 subunits of the proteasome. Alternative proteolytic systems may take the 
place of the proteasome leading to resistance to bortezomib (294-296). Targeting the PI3K/Akt 
signaling pathway may be a strategy to treat bortezomib resistant MCL, since the dual PI3K and 
mTOR inhibitor NVP-BEZ235 overcame bortezomib resistance in MCL cells. Activation of the 
endoplasmic reticulum (ER) stress pathway is correlated with resistance to doxorubicin-containing 
chemotherapy regimens, such as R-CHOP, in DLBCL patients. The 78-kDa glucose-regulated 
protein (GRP78), also known as immunoglobulin heavy chain binding protein, is an ER stress 
sensor commonly overexpressed in DLBCL that plays a role doxorubicin- and bortezomib-







1.2.19 Epigenetics  
Epigenetics plays a critical role in many pathological processes of cancer (299). Histone 
deacetylases (HDACs) play a central role in cancer epigenetics (300). HDACs catalyze the 
removal of acetyl groups from core histones, which leads to the compaction of chromatin and 
repression of transcription (301). HDACs have been implicated in promoting drug resistance in 
B-cell malignancies (302, 303). Thus, HDAC inhibitors (HDIs) are being investigated as a new 
therapeutic approach to treat B cell lymphomas (304, 305).  HDI-mediated inhibition of HDACS 
results in increased histone acetylation, which can reactivate silenced genes leading to the 
reversion of drug resistance (306-310).  
Preclinical studies revealed synergistic interactions between proteasome inhibitors (PIs) and 
HDIs in lymphoma (311, 312). Coadministration of subtoxic concentrations of PIs with HDIs 
(vorinostat) synergistically increased apoptosis in both GC- and ABC-DLBCL cells, suggesting 
that a strategy using irreversible PIs to enhance the activity of HDIs might be effective in 
DLBCL. In other examples, HDIs reversed mTOR (mammalian target of rapamycin) resistance 
through a phosphatase that antagonized mTORC2 activation (84), suggesting a combination of 
HDI and mTOR inhibitors as a strategy for overcoming mTOR resistance in DLBCL. The 
coadministration of HDIs with rituximab may be a strategy to reverse rituximab resistance in B-
cell lymphomas (313). HDIs enhanced the cytotoxic activity of rituximab by upregulating 
expression CD20 antigen on lymphoma cells. 
 
1.2.20 MSI instability  
MSIs are repetitive DNA sequences. Within MSIs, DNA polymerases are subject to slippage, 
and misalignments can form between the template and nascent strands. Mismatch repair (MMR) 
corrects these strand misalignments during DNA replication. MSI is a sign of deficient MMR 
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processes (314-318). In NHL, MSI may serve as a MMR biomarker that predicts lymphoma 
response to chemotherapy (319). MSI was found in 14% of tumors in NHL patients. Response to 
chemotherapy and outcomes were significantly worse in those NHL patients with MSI tumors. 
 
1.2.21 Stromal influences  
Stromal cells are an essential component of the bone marrow microenvironment that influences 
and supports tumor growth and survival (320-323). Resistance to chemotherapy can result from 
cytokines and growth factors released from stromal cells (320, 321). Bone marrow stroma can 
provide a protective ‘sanctuary site’ for lymphoma cells during chemotherapy (324), thus having 
an impact on the outcome of chemotherapy in DLBCL (325). Secretion of interleukin-4 and the 
integrin ligand VCAM-1 from stromal cells increase survival and rescue B cells from 
chemotherapy-induced apoptosis (326, 327). Another factor released from bone marrow stromal 
cells is the lymphoma cell adhesion induced B cell-activating factor (BAFF) protein, a member 
of the TNF superfamily of cytokines, which promotes B-cell activation, proliferation, and 
differentiation, thus enhancing B-lymphocyte survival (328-331). BAFF receptors are expressed 
on lymphomas originating from diverse subclasses of B cell lineages (332). Increased levels of 
BAFF were present in serum from NHL patients (332). Small-hairpin RNA depletion of BAFF 
increased sensitivity of lymphoma cells to chemotherapy and overcame stroma-mediated drug 
resistance. 
Stroma-produced survival signals can influence the expression, conformation, and protein–
protein interactions of Bax and Bcl-xL, which can then influence the sensitivity of a B cell 
lymphoma to chemotherapeutics (76, 333-337). Stroma-mediated activation of CD40 
upregulated Bcl-xL protein levels via activation of NFκB. VCAM-1-mediated signals repressed 
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conformational changes in Bax protein and prevented etoposide-induced formation of Bax–Bcl-
xL complexes. Stromal upregulation of IL-6 may contribute to the intrinsic chemoresistance 
commonly found in both primary and metastatic malignancies (338, 339). Additionally, tumor-
directed inflammatory responses originating in the stroma that release IL-6 may reduce the 
efficacy of genotoxic agents.  
Lymphocytes home into tissue stromas, which guide the lymphocytes by secreting chemokines 
and expressing ligands for lymphocyte adhesion molecules. In B cell lymphomas, the tumor cells 
retain the trafficking and homing ability of their normal counterparts (340-343). Lymphoma cells 
are directed to supporting stroma by chemokine receptors and adhesion molecules, where they 
receive survival and drug-resistance signals (344, 345). Stromal cells release chemokines, such 
as CXCL12 and CXCL13, which provide guidance for localizing B cells within lymph-node 
compartments (323, 346, 347). Lymphocyte homing requires the cooperation between 
chemokine receptors and adhesion molecules, such as integrins, CD44 and L-selectins (348). 
Moreover, accessory cells, including CD68þ macrophages and T cells, in the lymphoma 
microenvironment can influence the clinical outcome (349-351), indicating that crosstalk 
between lymphoma and stromal cells plays an important role in lymphoma progression and 
chemoresistance.  
FL patients frequently are initially sensitive to chemotherapy but then relapse. Highly 
tumorigenic FL cells exhibiting a cancer stem cell-like phenotype (FL-SC) were found to 
interact with follicular dendritic cells in a CXCL12/CXCR4-dependent manner to resist 
chemotherapeutics, indicating an important role for FL-SC and niche cell-signaling in 





1.2.22.1 Sphingosine kinase  
Upregulation of sphingosine kinase 1 (SphK1) frequently occurs in lymphomagenesis. SphK1 is 
associated with resistance to chemotherapy and radiotherapy (353, 354). SphK1 controls the 
‘sphingolipid rheostat’ by catalyzing the formation of the survival molecule, sphingosine-1-
phosphate, at the expense of the proapoptotic molecule, ceramide (355). SphK1 protein and 
mRNA levels showed increasing expression with increasing clinical grade of NHL (356). 
 
1.2.22.2 Geranylation  
Inhibition of protein prenylation (geranylgeranylation) can sensitize DLBCL to 
chemotherapeutics (357). Prenylation is a post-translational hydrophobic modification of 
proteins that facilitates the attachment of proteins to membranes. The lipid isoprenoid acts as a 
lipid anchor, which is essential for proper protein localization and biological function (358-360). 
Treatment with simvastatin, an inhibitor of protein farnesylation and geranylgeranylation, 
sensitized CHOP-resistant DLBCL cells to cytotoxic treatment (357). Coadministration of 
protein geranylgeranylation inhibitors and conventional chemotherapeutics thus may be a 
strategy for treating patients with CHOP refractory DLBCL. 
 
1.2.22.3 Zinc transporter  
Gallium nitrate is a clinically active agent in the treatment of lymphoma (361-365). Gallium 
binds to transferrin in the circulation, which targets it to transferrin receptors that are expressed 
on lymphoma cells (366-371). Gallium also acts on zinc metabolism pathways (372). 
Unfortunately, resistance to gallium can occur, which is caused by the upregulation of metal-
responsive transcription factor-1 activity and metallothionein expression (372). 
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Immunohistochemical staining of lymphomas showed that the metallothionein protein is variably 
expressed in different lymphomas. 
 
1.2.22.4 PRDM-1  
The positive regulatory domain I (PRDM1) protein regulates the differentiation of mature B 
lymphocytes to plasma cells (373, 374). The PRDM1 gene encodes 2 isoforms, PRDM1α and 
PRDM1β that are regulated by NFκB (375, 376). Those DLBCL cases that expressed PRDM1 
displayed more aggressive behavior and a poorer patient outcome (377). PRDM1β expression 
thus might serve as a prognostic marker for drug resistance in some types of DLBCL. 
 
1.2.22.5 ALDH  
The intracellular enzyme retinaldehyde dehydrogenase (ALDH) promotes resistance of MCL to 
chemotherapeutics (378-380). ALDH is a cytosolic enzyme required for the biosynthesis of all-
trans-retinoic acid and is highly expressed by normal hematopoietic and neural stem cells (381, 
382). ALDH is expressed in B cell lymphomas (383, 384) and can induce cyclophosphamide 
resistance in lymphoma cell lines (385-389). 
 
1.3 Summary and conclusions  
Both intrinsic genetic alterations as well as chemoprotective microenvironments can play roles in 
the cellular response of B cell lymphomas to chemotherapeutics. Given the genetic diversity of B 
cell lymphomas and differential antigen expression patterns across lymphoma subtypes, it is 
unlikely that a single small molecule or antibody-based therapeutic will effectively treat all 
categories of NHL. Overcoming drug resistance to current chemotherapeutic regimes in B-cell 
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lymphomas will require multitargeted combinatorial therapies to restore apoptotic pathways in 
tumor cells and inhibit prosurvival signaling from the stroma environment. 
With the exception of those patients eligible for allogeneic or autologous stem-cell 
transplantation, combination chemotherapy offers a potentially curative option for a subset of 
DLBCL patients (172). However, responses to current combination chemotherapy regimens (e.g. 
rituximab with cytoxan, hydroxyrubicin, oncovin, and prednisone) vary considerably depending 
on multiple factors, including disease stage and genetic profile, among others. In particular, 
patients with the ABC-DLBCL subtype, which is NFκB-dependent (37, 390), appear to have a 
significantly worse prognosis than other subtypes (391). Collectively, these considerations have 
motivated the search for more effective combinatorial treatment strategies in DLBCL that are 
pathway-targeted to specifically target tumor cells without toxicity to nonmalignant cells. 
Multitargeted combinatorial experimental therapies composed of new targets and conventional 
chemotherapeutics may provide more immediate hope for relapsed patients who have failed 
current chemotherapies. For example, preclinical studies have documented synergistic 
interactions between PIs, such as bortezomib and HDAC inhibitors in diverse malignant cell 
types (311, 392, 393). Targeting CD40 with dacetuzumab enhanced the antitumor activity of 
rituximab (CD20) in cell line and xenograft NHL models (394). In MCL, a sequence-dependent 
synergistic effect was observed with PIs in combination with cytarabine (395). Tipifarnib and 
bortezomib combination was well-tolerated and produced clinical responses in refractory acute 
leukemias (396). Multilevel inhibition of the PI3K/Akt/mTOR and cdc2/cdk1 cell-cycle 
pathways may be more effective in treating DLBCL patients that present with overactive Akt 
and cdc2/cdk1 (397). 
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Thus, understanding genotype-response relationships in NHL will be important for the effective 
use of new targeted therapies in the clinic. Responsiveness to multitargeted therapies will be 
predicted based on molecular markers to predefine patients who will most likely benefit from 
these targeted therapies. For instance, ‘BH3 profiling’ can identify those cells that are sensitive 
to the Bcl-2 antagonist ABT- 737 (398). Determining the activity of the NFκB pathway in 
DLBCL tumor biopsies by GEP can predict responsiveness to the IκB kinase inhibitor PS1145. 
Future approaches to NHL treatment will employ molecular signatures identified through GEP to 
provide prognostic information and to identify therapeutic targets in patients who relapse or 
those presenting with high risk disease to guide clinicians in designing a personalized approach 








Figure 1.1 Schematic representation of drug resistance pathways in B-cell lymphomas. 
PI3K/Akt is frequently activated, which leads to increased mTOR activity stimulating 
upregulation of multidrug resistance pumps (MDR, P-gp). Akt phosphorylates Bad and 14-3-3z, 
leading to binding and sequestration of the proapoptotic protein Bad and blocking to apoptosis. 
Upregulation of antiapoptotic proteins (Bcl-2, Mcl-1, XIAP, Bfl-1) can block chemotherapeutic-
induced intrinsic apoptosis. The Akt pathway can be activated by upregulation of miR-21, which 
represses expression of the Akt-negative regulator, PTEN. Activation of tyrosine receptor 
kinases (TRKs) can induce drug resistance by activating Akt through mTOR. TRKs can also 
activate NFκB, which upregulates Bfl-1 resulting in blocking of TNF- or Trail-induced extrinsic 
apoptosis. Upregulation of BCL6 blocks TGFβ-signaling through SMAD4. Glutathione 
transferases (GSTs) can suppress oxidative stress caused by reactive oxygen species (ROS) that 
are induced by chemotherapeutics. Histone deacetylases (HDACs) can promote resistance to 
rituximab combinatorial chemotherapies (R-CHOP) by upregulating mTOR and Bcl-2 and 
downregulating CD20. Mutation in the p53 gene causes defects in the DNA damage response 
and upregulation of multidrug resistance pumps (MDR, P-gp). Mutations in Atm can cause 
deficiencies in the p53-induce DNA damage response, leading to lack of expression of 
proapoptotic BH3 proteins (Bim, Puma, Noxa) and blocking of intrinsic apoptosis. 







1.4 Nuclear factor erythroid–related factor 2 (Nrf2) regulatory network 
The Nrf2, the master regulator of oxidative stress, activates the transcription of over 200 
cytoprotective genes (399). Under basal condition, Nrf2 is tightly under regulation of ubiquitin 
proteasome system. The Kelch-like ECH-associated protein 1 (Keap1)–cullin3 (Cul3)–ring-box1 
(Rbx1) E3-ligase is the primary regulator of Nrf2. However, E3 ubiquitin ligases beta-transducin 
repeat-containing E3 ubiquitin protein ligase (β-TrCP) and synoviolin (Hrd1) are Keap1-
independent negative regulators of Nrf2 system (400). Several antioxidant pathways with 
complementary functions are under control of Nrf2, including glutathione (GSH) production and 
utilization, thioredoxin (TXN) production and ultilization, and NADPH production. NAD(P)H: 
quinone oxidoreductase 1 (NQO1) and heme oxygenase (HMOX1) are other antioxidant 
enzymes that are controlled by Nrf2 (401). Notably, there several other Nrf2 target genes that are 
not involved in antioxidant functions. Altogether, the Nrf2 regulatory network protects against 
many diseases including neurodegenerative diseases, aging, cardiovascular disease, 
inflammation, and even initiation of many types of cancers (400, 402). Despite contribution to 
the maintenance of cellular homeostasis, uncontrolled Nrf2 hyper-activation is considered as the 
dark side of Nrf2 that promotes tumor growth and causes resistance to chemotherapeutics (403-
405).  
Interestingly, there are interactions between pathways involved in drug resistance in B-cell 
lymphomas (Figure 1.1) and Nrf2 regulation. PI3K/Akt phosphorylates Nrf2, which potentially 
is an important determinant of Nrf2 activity (406). Several studies demonstrated that PI3K/Akt 
activity is required for Nrf2 activation in different cancer cell lines (407, 408). Nrf2 upregulates 
anti-apoptotic protein Bcl-2 expression promoting cancer cell survival and chemoresistance 
(409). On the other hand, dissociation of Bcl-2 from the Nrf2 inhibitor, Keap1, leads to greater 
survival and chemoresistance (410). A recent study showed that TGF-β promotes tumor growth 
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and resistance to radiotherapy in A549 human lung cancer cells via ROS-mediated stimulation of 
Nrf2 activity (411). Tumor suppressor p53 suppresses the Nrf2-dependent transcription of ARE-
containing promoters and is therefore a transcriptional repressor of Nrf2 target genes (412, 413). 
By contrast, the cyclin-dependent kinase inhibitor p21 which is under control of p53 could 
upregulate Nrf2 activity. p21 inhibits the degradation of Nrf2 leading to upregulation of 
antioxidant genes (414). Negative or positive regulation of Nrf2 by p53 may trigger apoptosis or 
promote survival in cancer cells (412).  
Here, we will focus on the role of Nrf2 in metabolic-orientated regulation of oxidative stress in 
DLBCL. In chapter II, we will explore the regulatory effect of Nrf2 on glucose-6-phosphate 
dehydrogenase (G6PDH), where during oxidative stress, Nrf2 upregulates G6PDH providing 
reducing equivalents (NADPH) for the maintenance of a pool of reduced mitochondrial 
glutathione (GSH) to balance the redox state, which has a crucial role in cellular signaling and 
antioxidant defenses (415-417). We hypothesized that a Nrf2/G6PDH cascade is dysregulated in 
drug resistant DLBCL cells and manipulation of this cascade may change the tolerance of those 
cells to chemotherapy. 
In chapter III, we will describe an approach to develop drugs that focus on the cause of 
chemoresistance. We will define a novel non-toxic rifamycin derivative (RTI-79) as a potent 
chemosensitizer effective in multiple types of cancer cells. We will explore the mechanisms of 
action of RTI-79, where inhibition of Nrf2 plays a pivotal role in oxidative stress-mediated 
reversal of drug resistance in cancer cells.  






GLUCOSE-6-PHOSHPHATE DEHYDROGENASE MEDIATES CHEMORESISTANCE IN 
DIFFUSE LARGE B CELL LYMPHOMA *2
2.1 Introduction 
Non-Hodgkin’s lymphomas (NHLs) are a group of malignancies displaying many different 
clinical behaviors and thus prognoses (418). The majority (80-85%) of NHL arise from B cells 
that undergo clonal expansions during different stages of differentiation (419-421). DLBCL is an 
aggressive subtype of NHL (422, 423). The anthracycline-based CHOP chemotherapy regimen 
(consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone) in combination with 
rituximab (anti-CD20) has been the most effective treatment for DLBCL for over two decades 
(424). Unfortunately, approximately half of DLBCL patients develop a chemoresistant disease 
with a high mortality rate (425-428).  
Thus, characterization of the molecular basis of CHOP resistance is urgently needed to develop a 
rational strategy to overcome drug resistance (429, 430). Drug-sensitive cancer cells frequently 
exhibit higher basal ROS levels than their normal counterparts, partly due to oncogenic 
stimulation, increased metabolic activity, and mitochondrial malfunction (431-433). However, 
chemoresistant cancer cells frequently display upregulation of antioxidant pathways to 
antagonize ROS, thus making them resistant to anti-cancer agents that induce oxidative stress 
(401, 434-436).  
                                                          
* Reprinted from “Glucose-6-phosphate dehydrogenase mediates chemoresistance in diffuse 
large B cell lymphoma” by Seyed Hossein Mousavi-Fard, Timothy Davis, Deeann Wallis, Jim 




Nrf2 is an ROS sensor critical in regulating cellular redox status and activates expression of 
genes encoding for various antioxidant and cytoprotective enzymes (437-439). Normally, Keap1 
maintains low levels of Nrf2 by anchoring it within the cytoplasm and directing it for 
ubiquitination and proteasomal degradation (438, 440). High levels of ROS inhibit the enzymatic 
activity of Keap1, leading to decreased Nrf2 ubiquitination and degradation, and thus increased 
Nrf2 stability (441). As a result, Nrf2 migrates into the nucleus and works with other 
transcription factors to transactivate the antioxidant response elements (AREs) of cytoprotective 
genes, including G6PDH, to antagonize ROS and reduce oxidative injury (442-445). Constitutive 
dysregulated activation of Nrf2 can lower ROS levels causing resistance to chemotherapeutic-
induced oxidative stress (446). 
Activation of Nrf2 results in upregulation of G6PDH expression, indicating a pivotal 
contribution of Nrf2 in metabolic control of the redox state (442-444). G6PDH is the rate-
limiting enzyme of the pentose phosphate shunt (PPP) (447-449), which is an important pathway 
for recycling of cellular glutathione (GSH), a key scavenger of ROS (450). In the oxidative 
phase of the PPP, glucose 6-phosphate is irreversibly converted into ribulose 5-phosphate and 
CO2, thereby generating NADPH, a redox cofactor for many antioxidant enzymes (451). The 
NADPH produced is also used by glutathione reductase to reduce glutathione disulfide to 
glutathione (GSH). Increased G6PDH activity generates more reducing equivalents (NADPH) 
that can promote increased GSH generation through the PPP. The PPP is activated by Nrf2, thus 
generating more GSH, which scavenges ROS, thereby promoting reductive stress (decrease in 
ROS) and resistance to chemotherapeutics (416, 452). Consistent with this model, drug 
resistance was reversed by suppression of Nrf2 activity combined with depletion of GSH in 
adenocarcinoma cells (453).  
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We report here elevated Nrf2 and G6PDH activities in CHOP-resistant DLBCL cells. We 
hypothesized that a more reduced intracellular state (lower expression of ROS) promotes CHOP 
resistance in DLBCL cells. We generated CHOP-resistant cells from CHOP-sensitive DLBCL 
lines as a model to test our hypothesis (82, 83). We report here that CHOP-resistant DLBCL 
cells have a lower oxidative state (lower ROS) than their more drug-sensitive counterparts. Our 
data suggest a CHOP-resistance model in DLBCL whereby upregulated Nrf2 and G6PDH 
activities cause increased GSH levels that scavenge and reduce ROS levels, thus increasing 
tolerance to CHOP. Moreover, we present evidence that acquisition of CHOP resistance arises 
from the emergence of a population of Nrf2High/G6PDHHigh/ROSLow DLBCL cells, which survive 
repeated exposures to CHOP therapy. 
 
2.2 Materials and methods 
2.2.1 Antibodies and reagents  
Primary antibodies used were rabbit monoclonal anti-G6PDH (D5D2, Cell Signaling, Boston, 
MA, USA), rabbit monoclonal anti-Nrf2 (ab62352, abcam, Cambridge, MA, USA), and mouse 
monoclonal anti-actin (ab3280, abcam, Cambridge, MA, USA). Secondary antibodies used were 
polyclonal goat anti-rabbit immunoglobulins /HRP and polyclonal goat anti-mouse 
immunoglobulins/HRP (Dako, Carpinteria, CA, USA). Trans-Dehydroandrosterone (DHEA) 
was obtained from Sigma-Aldrich (St. Louis, MO, USA). The components of CHOP 
(cyclophosphamide, doxorubicin, vincristine, and prednisone) were obtained from Sigma-






2.2.2 Cell lines and culture conditions  
Human-derived CRL-2631 and SU-DHL-10 DLBCL cell lines were obtained from the American 
Type Culture Collection. Variants with relatively more tolerance to CHOP were derived by on 
and off cycles of CHOP treatment as described (83). The proportion of the four components used 
in CHOP treatment of DLBCL was consistent with the standard dosage CHOP therapy. The 
composition of CHOP consisted of cyclophosphamide, doxorubicin, vincristine, and prednisone 
at the clinical ratio of 80/5.5/0.16/11.1, respectively (424). Similar to patient CHOP regimen, 
cells were subjected to cycles of 5 days of CHOP treatment followed by 21 days of recovery in 
the absence of CHOP. Cells were initially selected with several cycles of 80 ng/ml CHOP. 
Greater than 99.9% of the cells died within 5 days of the first CHOP cycle, but a few cells were 
able to grow and proliferate. After several on-off cycles in 80 ng/ml CHOP, the viable cells were 
treated with several on-off cycles of a higher CHOP dose (160 ng/ml). Cycling with CHOP was 
continued until a cell population emerged that could survive and recover from 5-day exposures 
to 640 ng/ml CHOP (83). The CHOP-sensitive CRL-2631 (2631) and SU-DHL-10S (10S), and 
their relatively more CHOP-resistant G3 and SU-DHL-10R (10R) derivatives, respectively, were 
maintained in RPMI medium 1640 (Gibco; Thermo Fisher Scientific, Waltham, MA, USA) 
supplemented with 10 mM HEPES, 1.5 g/liter sodium bicarbonate, 1.0 mM sodium pyruvate, 4.5 
g/liter D-Glucose, antibiotic-antimycotic and 10% Fetal Bovine Serum (Gibco; Thermo Fisher 
Scientific, Waltham, MA, USA). 
 
2.2.3 Western Blotting  
Whole cell lysates were prepared by disrupting cells in a 2X Laemmli Sample Buffer (Bio-Rad 
Laboratories, Hercules, CA, USA) supplemented with 2-Mercaptoethanol (Sigma-Aldrich, St. 
Louis, MO, USA) and Protease/Phosphatase Inhibitor Cocktail (Cell Signaling, Boston, MA, 
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USA) at 95°C for 10 min. Protein concentrations were determined using the Quick Start 
Bradford protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Proteins were loaded (10 
µg/lane) onto 10% precast polyacrylamide Mini-PROTEAN Gels (Bio-Rad Laboratories, 
Hercules, CA, USA) according to the manufacturer’s instructions. Proteins were transferred from 
SDS gels to Immobilon PVDF transfer membranes (EMD Millipore, Billerica, MA, USA). Blots 
were pre-blocked with TBS-T20 buffer (0.1% Tween-20 and 5% nonfat dried milk in TBS) for 1 
hour at room temperature. Blots were then probed with primary antibody (anti-G6PDH; 1:1000, 
anti-Nrf2; 1:1000, anti-actin; 1:10000) in TBS-T20 buffer overnight at 4°C. Membranes were 
then washed three times each for 10 min in TBS-T20 and incubated with the appropriate HRP-
conjugated secondary antibody (anti-mouse; 1:5000; anti-rabbit; 1:1000) in TBS-T20 buffer for 
2 hours. Membranes were washed three times each for 2 hours with TBS-T20 buffer. 
Membranes were finally treated with Clarity Western ECL substrate (Bio-Rad Laboratories, 
Hercules, CA, USA) for 5 min and signal detection was performed on Blue Basic 
Autoradiography Films (GeneMate; Bioexpress, Kaysville, UT, USA). 
 
2.2.4 Measurement of intracellular GSH levels  
Intracellular GSH was measured using a monochlorobimane to react with GSH in intact cells to 
generate a blue fluorescent product (Cayman Chemical Co., Ann Arbor, MI, USA). Cells were 
treated with DMSO or DHEA and were cultured in a CO2 incubator overnight at 37 °C. The next 
day, samples were prepared according to the manufacturer’s protocol and 100 µl of Substrate 
Solution added to 1 million cells. After 30 min incubation at 37 °C, levels of GSH were 
measured in whole intact cells using the LSRFortessa X-20 flow cytometer (Becton 




2.2.5 Measurement of Intracellular reactive oxygen species’ levels  
Reactive Oxygen Species detection reagents were purchased from Thermo Fisher Scientific 
(Waltham, MA, USA). Total ROS levels were measured using CellROX Deep Red Reagent. 
Superoxide species were detected using MitoSox. Hydrogen peroxide species were detected 
using Dihydrocalcein AM. Hydroxyl radicals were detected using 3'-(p-Aminophenyl) 
fluorescein (APF). Cells were treated with drugs and cultured in a CO2 incubator overnight at 37 
°C. The fluorescent ROS indicators were added to cells at a final concentration of 5 μM and 
samples were incubated for 60 minutes at 37°C. FACS measurements were performed directly 
on the CellROX-, MitoSox-, Dihydrocalcein AM- or APF-labeled cells in phenol red-free RPMI 
using a LSRFortessa X-20 flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). 
 
2.2.6 G6PDH Assay 
G6PDH activity was determined by employing a Glucose-6-Phosphate Dehydrogenase Activity 
Assay Kit (Cayman Chemical Co., Ann Arbor, MI, USA) based on G6PDH’s ability to reduce 
NADP+ to NADPH, which then reacts with a detector to yield a fluorescent product (excitation: 
530-540 nm, emission: 585-595 nm). Assays were performed according to the manufacturer’s 
protocols.  
 
2.2.7 Measurement of intracellular NADPH levels  
The levels of cellular NADPH were determined by a NADP/NADPH Quantification Kit (Sigma-
Aldrich, St. Louis, MO, USA). Cells were washed with 1X PBS and extracted according to the 
manufacturer’s protocol. A Reaction Mix (containing NADP Cycling Buffer and NADP Cycling 
Enzyme Mix) was prepared and added to the cell lysates and standards. Finally, NADPH 
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developer was added to samples and NADPH levels were measured using a colorimetric plate 
reader at 450 nm. 
 
2.2.8 Cell viability assay 
Trypan blue staining was used to assess cell viability. Cells in suspension were mixed with an 
equal volume of 0.4% trypan blue stain (Gibco; Thermo Fisher Scientific, Waltham, MA, USA), 
loaded onto a hemocytometer (Bright-Line; Sigma-Aldrich, St. Louis, MO, USA), and cells 
counted using a microscope (Fisher Micromaster; Fisher Scientific, Pittsburg, PA, USA).  
 
2.2.9 Isolation of low and high oxidative state CRL-2631 DLBCL cells  
10 x 106 cells were incubated in 5 ml complete cell growth medium containing 5 μM CellROX 
Deep Red (Life Technologies; Thermo Fisher Scientific, Waltham, MA, USA) for 1 hour and 
then subjected to flow cytometry. Cells at the lower and higher extremes of the geometric means 
of the CellROX fluorescence were isolated by FACS sorting and propagated in culture. ROS 
levels were confirmed as high (2631Hi) or low (2631Lo) in the propagated populations by flow 
cytometry. 
 
2.2.10 Stable short hairpin RNA (shRNA) knockdown of Nrf2 and G6PDH 
Lentiviral particles expressing scrambled (SC-108080) or Nrf2 shRNA (SC-156128-V) or 
G6PDH shRNA (SC-60667-V) were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA). Lentiviral transduction of G3 and 10R (ctrl shRNA or Nrf2 shRNA), and 2631Lo 
(ctrl shRNA or G6PDH shRNA) cells were performed following the manufacturer’s protocol. 
Briefly, 106 cells in 1 ml of complete RPMI medium were plated onto 6-well plates. Next, 
transduction enhancer polybrene (SC-134220; Santa Cruz, CA, USA) was added to each well at 
37 
 
a concentration of 5 μg/ml, and 30 minutes later viral particles were added to each well at 
concentrations of 10 μl/ml (containing 50,000 transducing units). The following day, RPMI 
media containing viral particles were removed from the cells and replaced with fresh media. The 
day after, the media was removed and replaced with fresh media containing 5 μg /ml Puromycin 
dihydrochloride (SC-108071; Santa Cruz, CA, USA) to select the stable clones expressing 
corresponding shRNAs. The transduced cells were selected by puromycin selection, and 
subjected to Western blot to confirm Nrf2 and G6PDH knockdowns. 
 
2.2.11 Statistical analysis 
Data represent the mean ± SEM of results obtained from at least three independent experiments. 
The statistical package JMP 12 (SAS Institute Inc., Cary, NC, USA) was used for statistical 
analysis. Data were statistically assessed by paired t test (for conditions in which the same cell 
line was compared +/- treatments), and unpaired t test (for comparisons between different cell 
line derivatives). Also, bivariate analysis, and 1-way ANOVA using Tukey’s HSD, or Fisher’s 
test were used when appropriate, based on sample size. 
 
2.3 Results 
2.3.1 Differential expression of ROS in CHOP-sensitive and –resistant DLBCL cell lines  
DLBCL cell lines with acquired resistance to CHOP were derived by repeated “on-off” 
exposures to increasing concentrations of CHOP as previously described (83). As shown in 
Figure 2.1A, two variant DLBCL cell lines (G3 and 10R) exhibiting significantly more tolerance 
to CHOP were generated from the parental CRL-2631 and SU-DHL-10 cell lines. The CHOP 
concentration of 640 ng/ml composition (see methods) was used in these experiments, which 
resulted in remarkable cell death in CHOP-sensitive cells after 72 hours of treatment. As shown 
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in Figure 2.1A, the more CHOP-sensitive 2631 cell line exhibited about 57.25% cell death after 
72 hours in the presence of 640 ng/ml CHOP, whereas the more CHOP-resistant variant G3 cells 
continued to grow in the presence of CHOP for up to 72 hours. Similar to G3, 10R continued to 
grow under CHOP treatment. However, the rate of growth was slightly slower than G3 cells. In 
contrast, its parental 10S cell line displayed 94% cell death after 72 hours of CHOP treatment. 
The CHOP-resistant DLBCL lines consistently exhibited markedly lower levels of ROS than 











Figure 2.1 Differential expression of ROS in CHOP-sensitive and -resistant DLBCL cells. (A) 
1 x 106 cells/ml were treated with CHOP (640 ng/ml) from 0 to 72 hours and viable cells 
quantified by trypan blue staining. G3 and 10R represent the more CHOP-resistant variants 
derived by repeated on-off CHOP treatment of the 2631 and 10S parental lines. (B) ROS levels 
were analyzed by FACS (1x 106 cells/ml) in the parental CHOP-sensitive (2631, 10S) and the 
more CHOP-tolerant (G3, 10R) variant DLBCL cells using the CellROX total ROS fluorescent 
indicator. The CHOP-resistant cell lines exhibited lower ROS levels as indicated by the shift in the 
geometric mean of the FACS peak toward the left of the FACScan compared to their more CHOP-









2.3.2 Differential expression of Nrf2 and G6PDH proteins in CHOP-sensitive and resistant 
lymphoma cells  
There are precedents indicating a functional communication between Nrf2 and metabolism. 
First, Nrf2-dependent protection against oxidative stress relies on an intact PPP, which provides 
crosstalk between metabolism and ROS detoxification (416). Second, Hepatitis B virus (HBV) 
upregulates G6PDH expression via HBx-mediated activation of Nrf2, implicating a potential 
effect of HBV on the reprogramming of the glucose metabolism in hepatocytes, which may be of 
importance in the development of HBV-associated hepatocarcinoma (454). Moreover, 
upregulation of the Nrf2/G6PDH pathway has been reported in development of chemoresistance 
in non-small cell lung carcinoma (455). We therefore conducted Western blotting to compare the 
expression of Nrf2 and G6PDH proteins in CHOP-sensitive 2631 and 10S lymphoma cells and 
their resistant derivatives, G3 and 10R, respectively. As shown in Figure 2.2 (top panels), 
expression of Nrf2 and G6PDH proteins was significantly lower in the CHOP-sensitive 2631 and 
10S lines compared to the more CHOP-tolerant G3 and 10R derivatives. More specifically, Nrf2 
expression was 92.2% less in 2631 relative to G3, and 95.21% lower in 10S compared to 10R, as 
normalized to actin. Expression of G6PDH was 68.72% lower in 2631 compared to G3, and 





Figure 2.2 Differential expression of Nrf2 and G6PDH in CHOP-sensitive and -resistant  
 
                   DLBCL cells. (Upper panels) Higher expression of Nrf2 and G6PDH proteins was 
observed by Western blot in CHOP-resistant G3 and 10R lymphoma cells than in the more CHOP-
sensitive 2631 and 10S lines. Actin was used as loading control. (Lower panel) Quantification of 
Nrf2 and G6PDH protein expression was conducted by calculating the intensity (pixels) of Nrf2 












2.3.3 Chemosensitization of CHOP-resistant DLBCL via inhibition of G6PDH activity 
Since CHOP-resistant DLBCL cell lines expressed markedly higher levels of G6PDH protein, 
we investigated the role of G6PDH activity in mediating tolerance to CHOP. More G6PDH 
activity was observed in CHOP-resistant lines G3 and 10R compared with their more CHOP-
sensitive parents, 2631 and 10S, respectively (Figure 2.3A; 59.4 and 80.31% more, respectively), 
which correlated with the increased amounts of G6PDH protein expression in CHOP-resistant 
lines (Figure 2.2). However, the difference in G6PDH activity between 2631 cells and G3 cells 
(59.4%) was not as great as the difference in protein expression observed between the two cell 
lines (68.72%). Similarly, the difference between G6PDH activity and protein level between the 
10S and 10R cell lines was 80.31 and 92.8%, respectively.  
Cells were treated with the widely-used G6PDH inhibitor, Dehydroepiandrosterone (DHEA) 
(456-458), and their tolerance to CHOP determined by trypan exclusion viability assay. DHEA 
reduced the amount of G6PDH activity by 15.61 and 33.44% in G3 and 10R, respectively 
(Figure 2.3A). In addition, DHEA caused increased sensitivity to CHOP in G3 and 10R, as 
indicated by the 42.86 and 130.67% lower number of viable cells, respectively, after 72 hours of 
CHOP treatment compared to CHOP-treated only controls (Figure 2.3B). The growth rate of 
DMSO-treated control 2631, 10S, G3 and 10R cells were similar over the treatment period. 






Figure 2.3 Chemosensitization of CHOP-resistant DLBCL cell lines by a G6PDH inhibitor. 
(A) G6PDH activity was confirmed higher in CHOP-resistant G3 and 10R than in their more 
sensitive parental cell lines, 2631 and 10S. Treatment of cells with 100 µM DHEA for 4 hours 
significantly lowered G6PDH activity in CHOP-resistant cell lines. (B) 100 µM DHEA was added 
to the CHOP cocktail and the growth of cells assayed after 24, 48, and 72 hours by trypan blue 
exclusion dye to determine whether G6PDH activity is required for tolerance to CHOP. Treatment 
of CHOP-resistant G3 and 10R cells with a combination of 100 µM DHEA and CHOP resulted in 










2.3.4 DHEA promoted oxidative stress in CHOP-resistant DLBCL cell lines  
We hypothesized that downregulation of G6PDH activity (by DHEA) in CHOP-resistant cells 
would cause oxidative stress by decreasing NADPH and GSH levels, resulting in corresponding 
increases in ROS and increased sensitivity to CHOP. G3 and 10R cells produced 36.72 and 
46.50% higher levels of NADPH than their drug-sensitive parental cells, and DHEA 
significantly decreased NADPH levels in both G3 and 10R cells by 31.46 and 41.65%, 
respectively, compared to DMSO-treated control cells. Similarly, 70.88 and 72.36% higher 
levels of GSH were observed in G3 and 10R cells compared to 2631 and 10S, and DHEA 
significantly decreased GSH levels in both G3 and 10R cells by 11.59 and 37.77%, respectively, 
compared to DMSO-treated control cells (Figure 2.4B). Interestingly, DHEA brought the 
NADPH levels down in G3 and 10R cells to the same as their parental 2631 and 10S lines, 
respectively. As shown in Figure 2.4C, treatment of G3 and 10R cells with DHEA also caused a 





Figure 2.4 DHEA promotes oxidative stress in CHOP-resistant DLBCL cell lines. (A) 
Inhibition of G6PDH reduced NADPH levels in CHOP-resistant cells. CHOP-sensitive 2631 and 
10S showed significantly lower levels of intracellular NADPH levels compared to their respective 
CHOP-resistant counterparts, G3 and 10R. Treatment of CHOP-resistant cells with 100 µM 
DHEA for 4 hours significantly reduced the levels of NADPH in both G3 and 10R cells. (B) 
Inhibition of G6PDH reduced GSH levels in CHOP-resistant cells. CHOP-resistant cells showed 
higher levels of GSH than CHOP-sensitive cells. The addition of 100 µM DHEA for 16 hours 
significantly reduced GSH in both G3 and 10R CHOP-resistant cells. (C) Increases in ROS in 
DHEA-treated CHOP-resistant DLBCL cells. Levels of ROS in CHOP-sensitive cells (2631, 10S) 
were significantly higher than their respective CHOP-resistant counterparts, G3 and 10R. 16 hours 
of treatment with 100 µM DHEA produced significant increases in ROS in the CHOP-resistant 




2.3.5 Purification and Characterization of Low and High Oxidative State Cells from 
CHOP-naïve (sensitive) CRL-2631 Populations  
During initial experiments to select for CHOP-resistant DLBCL cells, we observed that 99.9% of 
the CRL-2631 and SU-DHL-10 cells died after five days of exposure to CHOP. We 
hypothesized that these few viable cells remaining after the initial CHOP exposures represented 
a small population of lower ROS-expressing, CHOP-resistant variants that were the ancestors of 
the CHOP-resistant G3 and 10R cell lines. To test this hypothesis, CHOP-naïve CRL-2631 cell 
populations were sorted based on CellROX fluorescence (ROS levels). Two distinct lower and 
higher ROS populations were isolated at the lower and higher 5% fluorescence intensities of the 
geometric mean, respectively. From these isolated populations, CRL-2631 cell lines expressing 
either higher (2631Hi) or lower (2631Lo) ROS levels were successfully established in culture 
(Figure 2.5A and B). These ROS levels in both the 2631Hi and 2631Lo cell populations have 
been stable for over one hundred cell passages. 2631Hi cells were significantly less tolerant to 
CHOP than 2631Lo, as indicated by the 76.25% fewer number of trypan-blue viable cells left 
after 72 hours of CHOP treatment (Figure 2.5C). The inclusion of DHEA (100 µM) to CHOP 
(640 ng/ml) resulted in increased sensitization of 2631Lo cells to CHOP (Figure 2.6A), as 
indicated by the 67.18% fewer numbers of viable cells after 72 hours of treatment compared to 
CHOP alone. Western blot revealed that 2631Lo cells expressed more Nrf2 and G6PDH than 
2631Hi cells (Figure 2.6B). Higher G6PDH activity (65.48% more) was observed in 2631Lo 
cells compared with 2631Hi cells, which correlated with the increased amounts of G6PDH 
protein expression in 2631Lo cells. Treatment of 2631Lo cells with DHEA caused a significant 
decrease of 27.44% in G6PDH activity (Figure 2.6C). DHEA also caused significant decreases 
of 28.30 and 30.71% in both NADPH (Figure 2.7A) and GSH (Figure 2.7B) levels, respectively. 
On the other hand, treatment of 2631Lo cells with DHEA generated 1.89-fold higher ROS 
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compared to DMSO-treated cells (Fig 2.7C). The higher expression of NADPH, GSH, and lower 
generation of ROS in 2631Lo cells compared to 2631Hi cells was a distinctive pattern very 
similar to that observed in the CHOP-sensitive/resistant 2631/G3 and 10S/10R cell line pairs. 
However, the G3 and 10R cells were acquired by selection in repeated “on-off” exposures to 
increasing concentrations of CHOP, whereas the 2631Hi/2631Lo cell pair was isolated from 














     
 
  
Figure 2.5 Isolation of Relative Higher and Lower Oxidative State CRL-2631 DLBCL Cells. 
(A) CHOP-naïve CRL-2631 cells were labeled with CellROX for 1 hour and then separated into 
high and low ROS-expressing populations by FACS as described under Methods. (B) Total ROS 
levels determined by CellROX in 2631Hi and 2631Lo, which are shown compared with that in the 
2631 and G3 cell lines. (C) The lower ROS-expressing 2631Lo cells were markedly more resistant 





Figure 2.6 Lower-ROS expressing 2631Lo cells are more tolerant to CHOP and have higher  
 
                   levels of Nrf2 and G6PDH than the higher-ROS expressing 2631Hi cells. (A) The 
growth of 2631Hi and 2631Lo cells was evaluated in absence or presence of CHOP cocktail by 
trypan blue exclusion dye. Treatment of 2631Lo cells with CHOP revealed that they are relatively 
more CHOP-resistant than 2631Hi cells. The addition of 100 µM DHEA to CHOP resulted in 
decreased tolerance to CHOP in 2631Lo cells. (B) Upper panel: Higher expression of Nrf2 and 
G6PDH protein was observed by western blot in 2631Lo than 2631Hi cells. Actin was used as 
loading control. Lower panel: Quantification of Nrf2 and G6PDH protein expression determined 
by calculating the intensity (pixels) of Nrf2 and G6PDH bands relative to the intensity of actin 
band. (C) Higher G6PDH activity was confirmed in 2631Lo cells than in 2631Hi cells. Treatment 
of 2631Lo cells with 100 µM DHEA for 4 hours significantly lowered G6PDH activity. * p˂0.05, 







Figure 2.7 Inhibition of G6PDH reduces NADPH and GSH levels in 2631Lo cells. (A) 2631Lo 
cells showed higher levels of NADPH than 2631Hi cells. A 4 hour incubation with 100 µM DHEA 
significantly reduced NADPH levels in 2631Lo cells. (B) 2631Lo cells expressed higher levels of 
GSH than 2631Hi cells. A 16 hour incubation of 2631Lo cells with 100 µM DHEA significantly 
reduced GSH level in 2631Lo cells. (C) DHEA caused a significant increase in levels of ROS in 
2631Lo cells. Levels of ROS in 2631Lo cells after 16 hours of treatment with 100 µM DHEA 
showed a significant increase compared to DMSO-treated cells. ** p˂0.01, *** p˂0.001 
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2.3.6 shRNA knockdown of Nrf2 promoted oxidative stress-mediated reversal of CHOP 
resistance in G3 and 10R cells 
We investigated the impact of Nrf2 knockdown on the reversal of CHOP-resistance through 
transduction of the CHOP-resistant G3 and 10R cell lines with lentivirus expressing Nrf2 
shRNA. Considering the proposed regulatory role of Nrf2 on G6PDH in our hypothesis, Nrf2 
shRNA knock down would be expected to downregulate G6PDH activity with corresponding 
decreases in NADPH and GSH, and increases in ROS. As shown in Figure 2.8A, Nrf2 shRNA-
transduced G3 and 10R cells showed reduced levels of Nrf2 protein compared to the scrambled 
shRNA controls. Nrf2 shRNA reduced the amount of G6PDH activity by 23.87 and 28.54% in 
G3 and 10R cells, compared to control shRNA cells, respectively (Figure 2.8B). Moreover, Nrf2 
shRNA significantly decreased NADPH levels in both G3 and 10R cells by 19.24 and 21.13%, 
respectively, compared to control shRNA cells (Figure 2.9A). GSH levels also decreased in G3 
Nrf2 shRNA and 10R Nrf2 shRNA cells by 21.88 and 21.08%, compared to G3 control shRNA 
and 10R ctrl shRNA cells respectively (Figure 2.9B). Correspondingly, Nrf2 knockdown caused 
a 64.84% and 84.67% increase in intracellular levels of ROS in G3 and 10R cells compared to 
control cells, respectively (Figure 2.9C). shRNA knockdown of Nrf2 resulted in increased 
sensitization of G3 Nrf2 shRNA and 10R Nrf2 shRNA cells to CHOP (Figure 2.9D), as 
indicated by the 64.42 and 81.63% fewer numbers of viable cells after 72 hours of treatment 





Figure 2.8 Knockdown of Nrf2 reduces G6PDH protein expression and activity in G3 and  
 
                   10R cells. (A) Nrf2 shRNA transduction downregulated the expression of Nrf2 and 
G6PDH proteins. (Upper panel) Lower levels of Nrf2 and G6PDH proteins in G3 Nrf2 shRNA 
and 10R Nrf2 shRNA was observed by western blot compared to G3 (control) ctrl shRNA and 10R 
control (ctrl) shRNA, respectively. Control shRNA did not have any effect on Nrf2 or G6PDH 
expression in G3 and 10R cells. (Lower panel) Quantification of Nrf2 and G6PDH protein 
expression was determined by calculating the intensity (pixels) of Nrf2 and G6PDH bands relative 
to the intensity of actin band. (B) Nrf2 shRNA transduction lowered G6PDH activity in G3 and 









Figure 2.9 Knockdown of Nrf2 promotes oxidative stress and reduced tolerance of G3 and  
 
                   10R cells to CHOP. (A) Knockdown of Nrf2 reduces NADPH levels in CHOP-
resistant cells. G3 and 10R transduced with the control scrambled shRNA showed similar levels of 
intracellular NADPH levels as the non-transduced G3 and 10R cells, respectively. Knockdown of 
Nrf2 by shRNA significantly reduced the levels of NADPH in both G3 and 10R cells. (B) 
Knockdown of Nrf2 reduces GSH levels in CHOP-resistant cells. Both G3 Nrf2 shRNA and 10R 
Nrf2 shRNA cells showed significantly lower levels of GSH than their respective scrambled 
shRNA controls. (C) Knockdown of Nrf2 increased ROS production in CHOP-resistant DLBCL 
cells. Levels of ROS were significantly higher in G3 Nrf2 shRNA and 10R Nrf2 shRNA compared 
to their respective scrambled shRNA control cells. (D) Knockdown of Nrf2 reduces the tolerance 
of resistant DLBCL cells to CHOP. Both G3 and 10R cells transduced with Nrf2 shRNA cells 
were more sensitive to CHOP than control cells as indicated by the significantly decreased the 









2.3.7 shRNA knockdown of G6PDH promoted oxidative stress-mediated reversal of CHOP 
resistance in 2631Lo cells 
We investigated the impact of G6PDH knockdown on CHOP-resistance through transduction of 
the CHOP-resistant 2631Lo cell line with lentivirus expressing G6PDH shRNA. As shown in 
Figure 2.10A, G6PDH shRNA-transduced 2631Lo cells showed 58.06% reduced the level of 
G6PDH protein compared to the scrambled shRNA control. However, G6PDH knockdown 
didn’t show a significant effect on Nrf2 protein in 2631Lo cells. G6PDH shRNA reduced the 
amount of G6PDH activity by 18.19% in 2631Lo cells, compared to control shRNA cells (Figure 
2.10B). Consequently, levels of NADPH and GSH decreased in 2631Lo G6PDH shRNA cells by 
18.91 and 18.46%, respectively, compared to 2631Lo ctrl shRNA cells (Figure 2.11A-B). 
Correspondingly, G6PDH knockdown caused a 57% increase in intracellular levels of ROS in 
2631Lo cells compared to control cells (Figure 2.11C). shRNA knockdown of G6PDH resulted 
in increased sensitization of 2631Lo G6PDH shRNA cells to CHOP (Figure 2.11D), as indicated 
by the 30.02% fewer numbers of viable cells after 72 hours of treatment compared to 2631Lo 





Figure 2.10 G6PDH shRNA transduction downregulated the expression of G6PDH protein. 
(A) Lower levels of G6PDH protein in 2631Lo G6PDH shRNA was observed by western blot 
compared to 2631Lo control (ctrl) shRNA. However, no significant difference was observed in 
Nrf2 expression between samples (Upper panel). Quantification of Nrf2 and G6PDH protein 
expressions were determined by calculating the intensity (pixels) of Nrf2 and G6PDH bands 
relative to the intensity of actin bands (Lower panel). (B) G6PDH shRNA transduction lowered 
G6PDH activity in 2631Lo cells. Control shRNA did not affect G6PDH activities in 2631Lo 









Figure 2.11 Knockdown of G6PDH promotes oxidative stress and reduced tolerance of  
 
                     2631Lo cells to CHOP. (A) Knockdown of G6PDH reduces NADPH level in 
CHOP-resistant cells. While knockdown of G6PDH by shRNA significantly reduced the levels 
of NADPH in 2631Lo G6PDH shRNA cells, 2631Lo ctrl shRNA cells showed similar levels of 
intracellular NADPH as the non-transduced 2631Lo cells. (B) Knockdown of G6PDH reduces 
GSH level in CHOP-resistant cells. 2631Lo G6PDH shRNA cells showed significantly lower 
levels of GSH than their respective scrambled shRNA controls. (C) Knockdown of G6PDH 
increased ROS production in CHOP-resistant DLBCL cells. Levels of ROS were significantly 
higher in 2631Lo Nrf2 shRNA cells compared to their shRNA control cells. (D) Knockdown of 
G6PDH reduces the tolerance of resistant DLBCL cells to CHOP. 2631Lo G6PDH shRNA cells 
were more sensitive to CHOP than control cells as indicated by the significantly decreased the 
















2.3.8 Modulation of Nrf2 and G6PDH affects primarily superoxide/hydrogen peroxide 
species of ROS 
The types of ROS species in sensitive and resistance cells were characterized with fluorescent 
indicators specific for either superoxide, hydrogen peroxide, or hydroxyl radicals (Figure 2.12). 
Higher levels of all forms of ROS investigated were detected in sensitive than in resistant cells 
(Figure 2.12A-C). However, downregulation of either G6PDH (by DHEA or shRNA) or Nrf2 
(by shRNA) caused significant increases in superoxide/hydrogen peroxide but not hydroxyl 
radicals. For instance, while there were significant differences in superoxide levels between 
2631vs G3, 10S vs 10R, and 2631Hi vs 2631Lo cells, treatment of G3, 10R, and 2631Lo cells 
with DHEA caused a 1.89, 3.41-, and 3.19-fold increase in intracellular levels of superoxide 
compared to DMSO treated cells, respectively. Moreover, G3 Nrf2 shRNA and 10R Nrf2 
shRNA cells generated 0.63- and 1.37- fold increases in intracellular levels of superoxide 
compared to G3 ctrl shRNA and 10R ctrl shRNA cells respectively. In addition, 2631Lo G6PDH 
shRNA cells generated 1.05- fold increases in intracellular levels of superoxide compared to 
2631Lo ctrl shRNA (Figure 2.12A). There also was a significant difference in intracellular 
hydrogen peroxide levels between resistant vs sensitive lymphoma cells, and treatment with 
DHEA, and transduction with Nrf2 shRNA and G6PDH shRNA lentiviral particles slightly 
increased the levels of intracellular hydrogen peroxide (Figure 2.12B). On the other hand, 
despite the differences in intracellular levels of hydroxyl radicals between resistant vs sensitive 
lymphoma cells, neither DHEA treatment nor Nrf2/G6PDH shRNA transduction induced 








Figure 2.12 Characterization of ROS species in DLBCL cell lines. DHEA, Nrf2 shRNA, and  
 
                    G6PDH shRNA caused primarily increases in superoxide and hydrogen  
 
                     peroxide, but not hydroxyl radicals. (A) Mitosox superoxide indicator revealed 
higher superoxide in sensitive 2631, 10S, and 2631Hi cells than in their more CHOP-resistant 
counterparts, G3, 10R, and 2631Lo, respectively. DHEA, Nrf2 shRNA, and G6PDH shRNA 
induced increases in superoxide in CHOP-resistant cells. (B) The dihydrocalcein-AM indicator 
revealed higher hydrogen peroxide species levels in CHOP-sensitive cells than in resistant cells. 
DHEA, Nrf2 knockdown, and G6PDH knockdown caused a slight increase in production of 
hydrogen peroxide in CHOP-resistant lymphoma cells relative to control cells. (C) The APF 
indicator revealed markedly higher hydroxyl radicals in CHOP-sensitive cells than in resistant 
cells. However, DHEA or Nrf2 knockdown or G6PDH knockdown didn’t induce increases in 





In normal cells during oxidative stress, Nrf2 upregulates G6PDH providing reducing equivalents 
(NADPH) for the maintenance of a pool of reduced mitochondrial glutathione (GSH) to balance 
the redox state, which has a crucial role in cellular signaling and antioxidant defenses (415-417). 
We observed that CHOP-resistant DLBCL cell lines expressed a lower oxidative state (ROS) 
and increased expression of anti-oxidant Nrf2 and G6PDH genes than their more drug-sensitive 
counterparts. Based on our data, we propose that alterations in the Nrf2/G6PDH pathway can 
promote a higher reductive (lower oxidative) state that drives resistance to oxidative stress-
inducing chemotherapeutics (Figure 2.13).  
We utilized DHEA as an adjuvant to the widely used CHOP regimen and transduced G3 and 
10R cell lines with Nrf2 shRNA and 2631Lo cell line with G6PDH shRNA to determine a role 
for the Nrf2/G6PDH cascade in CHOP resistance. The following results indicated a role for the 
Nrf2/G6PDH pathway in oxidative stress-mediated drug resistance in lymphoma cells. First, we 
observed increased expression of both Nrf2 and G6PDH in CHOP-resistant variants derived by 
“on-off” treatments of sensitive cells with increasing concentrations of CHOP. Second, G6PDH 
protein expression and enzymatic activity were significantly higher in CHOP-resistant 
lymphoma cells compared with their more CHOP-sensitive parent cells, which also correlated 
with the lower ROS levels in CHOP-resistant cells. Third, higher expression of G6PDH 
correlated with higher NADPH and GSH in CHOP-resistant cells. Fourth, the G6PDH inhibitor, 
DHEA, sensitized CHOP-resistant cells to CHOP. DHEA inhibited G6PDH activity in a time- 
and dose-dependent manner, which was correlated with declines in NADPH and GSH and 





Figure 2.13 A model for the role of the Nrf2/G6PDH pathway in driving lower ROS  
 
                     expression and CHOP chemoresistance in DLBCL. Repeated exposures to CHOP 
treatment cause a chronic activation of Nrf2, which constitutively upregulates the G6PDH gene 
and thus increased G6PDH activity. G6PDH increases NADPH production through the PPP, which 
leads to increased synthesis of GSH, thus driving down ROS levels in the cell. The resulting 












The inhibition of G6PDH activity and consequently NADPH production by DHEA were early 
events occurring after 4 hours of treatment of CHOP-resistant lymphoma cells with DHEA. On 
the other hand, the reduction in GSH and induction of ROS generation occurred later after 16 
hours of DHEA treatment. This time sequence might be expected if GSH and ROS are 
downstream to G6PDH and NADPH. Fifth, transduction of G3 and 10R cells with Nrf2 shRNA 
significantly downregulated the expression of Nrf2, and consequently G6PDH (both protein 
expression and enzymatic activity). Sixth, transduction of 2631Lo cells with G6PDH shRNA 
significantly downregulated the expression of G6PDH (both protein expression and enzymatic 
activity). However, as expected, G6PDH shRNA knockdown didn’t affect the expression of Nrf2 
protein. Finally, Nrf2 knockdown increased the sensitivity of resistant G3 and 10R cells to 
CHOP and G6PDH knockdown increased the sensitivity of resistant 2631Lo cells to CHOP. 
Similar to DHEA, there was a positive correlation between shRNA knockdown of Nrf2/G6PDH 
with declines in NADPH and GSH, and a high negative correlation with increases in ROS 
(primarily superoxide/hydrogen peroxides).  
Although higher G6PDH activity was clearly associated with higher G6PDH protein expression 
in CHOP-resistant cell lines, the difference in G6PDH enzyme activity between CHOP-resistant 
and -sensitive cells was not absolutely correlative with respect to G6PDH protein level. For 
instance, the difference in enzyme activity of G6PDH between 2631 cells and G3 cells was 
59.4% but the difference in expression G6PDH protein level between the two cell lines was 
68.83%. For the 10S and 10R lines, the difference between G6PDH activity and protein 
expression was 80.31 vs 92.8%, respectively. The basis for the discrepancies in G6PDH protein 
expression and activity is currently not clear. However, G6PDH activity is regulated through 
phosphorylation by protein kinases. Differential phosphorylation might be responsible for the 
lack of strict correlation between G6PDH activity and protein levels between the CHOP-
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sensitive and –resistant cell lines (459-461). Thus, further work is ongoing to characterize the 
phosphorylation state of G6PDH in CHOP-sensitive and -resistant cell lines. 
We have previously reported the upregulation and roles of the anti-apoptotic 14-3-3zeta and Akt 
protein kinase in mediating CHOP resistance in DLBCL (82, 83). Of particular interest relevant 
to this report is the reported interaction of 14-3-3zeta with several redox enzymes and glucose-6-
phosphate isomerase (GPI) (462-464). In addition, PI3K/Akt signaling augments the nuclear 
accumulation of Nrf2 and enables Nrf2 to upregulate G6PDH to promote metabolic activities 
that support cell proliferation in addition to enhancing cytoprotection (452, 465). We thus plan to 
investigate potential roles for 14-3-3zeta and PI3K/Akt in Nrf2/G6PDH-mediated CHOP 
resistance in DLBCL. 
We were able to isolate CHOP-resistant variants from CHOP-naïve CRL-2631 cell populations 
that resembled CHOP-resistant cells (Nrf2High, G6PDHHigh, ROSLow) derived by repeated 
exposures to CHOP (acquired resistance). We propose that a specific type of CHOP-resistant 
lymphoma cell expressing the Nrf2High, G6PDHHigh, ROSLow phenotype may be selected for and 
amplified during repeated cycles of CHOP regimens, providing one possible explanation of why 
DLBCL can relapse in patients in clinical remission. We have not observed any differences in 
the expression of known cancer stem cell markers (CD44+, CD24-, CD133+, Notch) between 
CHOP-resistant and –sensitive cells or between CRL-2631Hi and CRL-2631Lo cells (data not 
reported). Moreover, no differences in the expression of the hypothesized lymphoma stem cell 
marker, ALDH (466), was observed between CHOP–resistant and –sensitive cells. Also, no 
differences in enzymatic activity of glutathione s-transferases (GST), which mediate ROS 
detoxification by utilizing GSH as a substrate (467), were observed between CHOP–resistant 
and –sensitive cells (data not shown). Further work is warranted along these lines and current 
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studies are thus concerned with applying RNAseq to identify additional specific markers that 
might characterize 2631Lo, 10R, and G3 cells as a specific type of lymphoma cell with the 
potential to initiate and propagate a CHOP-resistant disease phenotype.  
Based on our data, we propose a Nrf2/G6PDH model (Figure 2.14) for the acquisition of CHOP-
resistance in DLBCL. In this model, repeated cycles of on-off treatments with CHOP lead to 
selective amplification and emergence of a small population of cells expressing higher levels of 
the Nrf2/G6PDH pathway. An increased reductive state in these cells confers an increased 
tolerance to oxidative stress-inducing chemotherapeutics such as doxorubicin, a component of 
the CHOP cocktail. The mechanism driving a lower oxidative state in these resistant cells is 
upregulation of G6PDH catalyzing the production of NADPH via the PPP. NADPH is a 
substrate for glutathione reductase that regenerates GSH to detoxify ROS. NADPH is also 
required for growth and proliferation. Nrf2 directly targets the upregulation of G6PDH in 
CHOP-resistant cells. Our model proposes that the targeted destruction of these CHOP-resistant 
Nrf2High/G6PDHHigh/ROSLow cells with a combination therapy of Nrf2/G6PDH pathway 







Figure 2.14 Model for the emergence of acquired chemoresistance in DLBCL. We propose 
that resistance to CHOP is caused by the selected emergence during repeated cycles of CHOP 
treatment of a small population of CHOP-resistant cells that express high Nrf2 and G6PDH, and 
low ROS. High Nrf2/G6PDH activity drives increased expression of GSH that drives down ROS, 
thus giving cells the capacity to resist chemotherapeutics that induce oxidative stress. The 
Nrf2High/G6PDHHigh/ROSLow cells outgrow and outlive the more CHOP-sensitive 













DEVELOPMENT OF NOVEL, NON-TOXIC RIFAMYCINS THAT REVERSE DRUG 
RESISTANCE IN CANCER *3 
3.1 Introduction 
The cure rate and progression free survival rate for many cancers have not changed considerably 
in the past two decades. Ovarian cancer patients have an approximately 70% relapse rate within 
two years, and most relapse patients do not respond to second line therapeutics (468). Though 
there have been significant improvements for other cancers due to new drugs, such as Rituximab 
for NHL, non-responsive tumors remain a significant cause of annual mortality. This is 
especially true for patients with double and triple hit lymphomas (DHL and THL) due to 
inherent drug resistance. Pharmacologic resistance in cancer is widespread and not restricted to 
specific cancer types or drugs. Currently, there are no chemotherapies available that specifically 
target drug resistant cancer. Therefore, identification of novel strategies and therapeutics to 
combat resistance is crucial. 
Resistance can arise through multiple mechanisms, including the reduction of intracellular ROS 
(469-473). High intracellular ROS levels in cancer cells is common due to the Warburg effect 
(401), and it renders neoplastic cells more sensitive to ROS-inducing treatments such as 
doxorubicin chemotherapy and radiation. Recent evidence shows that many cancers develop 
altered antioxidant response systems to overcome elevated ROS levels, with a resultant decrease 
in sensitivity to chemotherapy (402, 474-477). Because higher ROS levels in cancer cells are 
                                                          
* Reprinted from “Development of novel, non-toxic rifamycins that reverse drug resistance in 
cancers” by Deeann Wallis, Nian Zhou, Dwight Baker, Seyed H. Mousavi-Fard, Kimberly 
Loesch, Stacy Galaviz, Qingan Sun, Carolina Mantilla Rojas, David W. Threadgill, Maureen T. 
O'Brien, Fred J. Clubb, Thomas Ioerger, Michael DeJesus, Wen Dong, Gwen Seemann, Theresa 
Fossum, Steve Maxwell, and James C. Sacchettini, 2017. Manuscript submitted for publication 
to Nature Medicine. 
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often a prerequisite for chemotherapy drug efficacy, an agent that forces the production of ROS 
or inhibits antioxidant response mechanisms would theoretically increase susceptibility to 
chemotherapy. 
Though controversial, the importance of ROS in the action of antibiotics has also been well 
characterized (478-486). For example, while rifamycins primarily mediate their antibacterial 
activity through inhibition of bacterial RNA polymerase, they also have additional 
pharmacological properties including the ability to undergo redox cycling with resultant 
formation of ROS. This is supported by the finding that ROS may enhance bactericidal activity 
of rifamycin SV (487). The oxidation of the quinone moiety of rifamycin SV is catalyzed by 
metal ions resulting in the production of superoxide (488, 489), which damages DNA (490, 491). 
Moreover, both rifamycin SV and rifabutin have been shown to redox cycle and produce 
superoxide in rat liver microsomes (492, 493). 
 
3.2 Materials and methods  
3.2.1 Cell lines and tissue culture  
Cell lines were obtained from the following sources: ATCC –OVCAR-3, SK-OV-3, CRL-2631, 
MES-Dx5, HL-60, HL-60 Mx, U2-OS, Panc-1, MOLT4 and HDF; the National Cancer Institute 
Division of Cancer Treatment and Diagnosis Tumor/Cell Line Repository – NCI/ADR-RES, 
OVCAR-8, and OVCAR-5; Dr. Eric Davis at MD Anderson Cancer Center provided many cell 
lines as a kind gift – U-2932, SU-DHL-4, SU-DHL-6, SU-DHL-10, OCI-Ly 19, HBL- 1, HT, 
and WSU-FSCCL; eGFP-ADR-RES were a kind gift from the Michael Gottesman Lab at NCI. 
All cells were cultured in RPMI 1640 media + 10% FBS except for the SK-OV-3, MES-Dx5, 
and U2-OS cells which were cultured in McCoy’s 5a plus 10% FBS; and Panc-1 and HDF cells 
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which were cultured in DMEM plus 10% FBS. Cultures were passaged every 3-5 days as 
necessary. 
 
3.2.2 Creation of G3 drug-resistant NHL cell line 
CRL-2631 cells were treated with on/off cycles of CHOP composed of 0.83 µM 4HC; 0.057 µM 
Dox; 0.01 µM Vincristine; and 0.186 µM Prednisone.  
 
3.2.3 HTS and identification of rifabutin  
G3 cells were screened in the presence of CHOP and 5 µM compounds. Importantly, as a 
counter screen for undesired cytotoxics, compounds were tested alone at 5 μM in the drug 
sensitive parental CRL-2631 cells; compounds which demonstrated an IC25 or greater in the 
CRL-2631 cell line were considered cytotoxic and eliminated from further study. Hits were 
defined as greater than three standard deviation units below the mean of the population, and this 
resulted in 292 compounds that were identified. The majority of the most potent hits came from 
the NIH clinical collection; rifabutin, verapamil, lercanidipine, miltefosine, econazole, 
terfenidine, nefazadone, ketoconazole, and FK-506 (tacrolimus) were some of the most potent 
identified. Hits were then prioritized for testing in ratio “checkerboard assays”, e.g. assay done 
while varying more than one concentration of drug in order to define the compounds most 
synergistic with the DOX component of CHOP. 
 
3.2.4 Cell viability assays 
We utilized 2 viability assays: resazurin-based and MTT based. For resazurin: 40 µl of cells 
were plated in appropriate media at various densities based on growth rates into 384-well plates. 
Suspension cells were treated immediately with compounds, but adherent cells were allowed 
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several hours to attach prior to compound addition. Cells were cultured for 48 hours at which 
point 40 ng/ml resazurin was added. After 16-24 hours fluorescent signal was read on a plate 
reader. Percent control growth was determined by comparing the growth of cells in the presence 
of the compound to the growth with no compound. 
For the MTT assay, we utilized the MTT cell growth Assay kit from Millipore according to the 
manufacturer’s directions. 
 
3.2.5 Drug-like diversity library  
Our custom in-house diversity library is designed to offer compounds with drug-like properties 
but low redundancy for exploring a wide range of chemical space to identify inhibitors with 
novel structures. This library was constructed such that each compound has a non-redundant 
chemical structure, minimizing the bias of many existing libraries which often contain many 
variations of common scaffolds. Thus, we can achieve similar breadth of screening with minimal 
time and resources compared to a very large ultra-high throughput compound collection. This 
diversity library was designed by combining structures from over 3 million compounds, and 
selecting a diverse and representative subset using a clustering algorithm. An incremental 
algorithm was then used to select a representative subset that covered the entire space, while 
guaranteeing that no pair of compounds had a chemical similarity greater than 0.7. 
 
3.2.6 Calculation of combination index 
Constant ratio dose response assays were conducted in triplicate on G3 and ADR-RES cell lines 
to determine the extent of synergy between the drugs. Normalized inhibition data were analyzed 
using CompuSyn software. 
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3.2.7 Statistical analysis – Determination of IC50 for chemotherapeutics with and without 
RTI-79 
Cell lines were treated with chemotherapeutics in dose response both with and without RTI-79. 
All assays were performed in triplicate. We utilized Graph Pad Prism and began by transforming 
the X values (compound concentration) to X=Log(X). Next, we performed a nonlinear 
regression curve fit of the transform; log (inhibitor) vs. dose response (three parameter) to 
determine IC50. Individual fitted midpoints within each cell line were compared using the extra 
sum-of-squares F test to determine if the best-fit values of selected unshared parameters differed. 
Significance was set at p<0.05. 
 
3.2.8 Mouse xenografts 
107 cells were injected sc into the left and right flanks of 6-8 week old female mice. SCID mice 
were used for NHL xenografts and nude mice were used for ovarian cancer xenografts. Once 
tumors were established and growing mice were assigned to treatment arms and treatments were 
begun. Tumor volume was monitored every other day, three times per week by caliper and 
calculated as (L*W*W)/2. Data are plotted as percent change in tumor volume according to: 
((VDay X-VDay 0)/(VDay 0 ))*100; where V= volume; Day 0 is the day of treatment initiation, Day X 
is any subsequent day. In the first study, WSU xenografts were implanted into SCID mice and 
treated 12 days later when tumor volume was approximately 375 mm3 with saline (once per 
week), 3.3 mg/kg DOX iv (once per week), 25 mg/kg oral RTI-79 (twice weekly on Days 1 and 
2) or a simultaneous combination of iv DOX once weekly (Day 1) and oral RTI-79 (twice 
weekly on Day 1 and 2). Mice received two cycles of treatment. In the second study, WSU 
xenografts were implanted into SCID mice and treated 11 days later when tumor volume was 
approximately 165 mm3 weekly with saline, 12 mg/kg etoposide given on days 1, 2, and 3 of 
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each week, 25 mg/kg RTI-79 given on days 1, 2, and 3 of each week, or etoposide plus RTI-79 
given on days 1, 2, and 3. Mice received three cycles of treatment. In the third study, nude mice 
were injected with ADR-RES cells and treated 9 days later when tumor volume was 
approximately 90 mm3 with once weekly saline, 7 mg/kg DOXIL iv, 25 mg/kg oral RTI-79 given 
on days 2 and 3, or a combination of iv DOXIL on Day 1 and oral RTI-79 on days 2 and 3. Mice 
received 6 rounds of treatment. In the fourth study, SK-OV-3 cells were injected into nude mice 
and treated 3 weeks later when tumor volume was approximately 100 mm3 once weekly with 
saline, 3mg/kg DOXIL on Day 1, 25 mg/kg oral RTI-79 on days 2 and 3, iv DOXIL on Day 1 
and 25 mg/kg oral RTI-79 on days 2 and 3, or iv DOXIL on Day 1 and 25 mg/kg oral rifabutin 
on days 2 and 3. Mice received 3 rounds of treatment. 
Tumor growth delay was evaluated and percent change in tumor growth based on the starting 
volume on the day prior to the first treatment i.e. ((Vt=X-Vt=0)/Vt=0))*100. Student’s t-test was run 
to evaluate statistical significance between groups. 
 
3.2.9 ROS quantitation and FACS: CellROX, MitoSOX, dihydrocalcein-AM, and APF  
Cells (1 x 106) were incubated with 1 µl of the ROS indicators CellROX, MitoSOX, 
dihydrocalcein-AM, or APF (Life Technologies) in 1 ml complete RPMI for 0-1 hour. Cells 
were then analyzed directly by flow cytometry at appropriate absorption/emission maxima. 
CellROX detects total ROS, whereas MitoSOX detects specifically superoxide, dihydrocalcein-
AM labels hydrogen peroxide, and aminophenyl fluorescein (APF) labels hydroxyl radicals. 






3.2.10 CellROX imaging 
Cells were plated at 20,000 - 50,000 cells per well in 96-well optical imaging plates. CellROX (5 
µM) (Invitrogen Cat # C10422) and compounds were added simultaneously in fresh media to 
triplicate wells and imaged on a GE INCell Analyzer after 30-60 minutes to detect fluorescent 
signal. As necessary cells were then fixed in 4% PFA and stained with DAPI and the same fields 
were reimaged to obtain a cell count. Images were analyzed using the INCell Developer software 
to determine cell count and CellROX intensity. Values were averaged over the triplicates and 
SEM calculated. 
 
3.2.11 Oxidation sensitive GFP construct 
Ratiometric rhoGFP fluorescence detectors were used to examine RTI-induced redox changes in 
real-time in cells. The reduction-oxidation sensitive green fluorescent protein (roGFP) is a redox 
biosensor that is retained in the cytoplasm (494). The resulting redox-sensitive protein has 
excitation maxima at 400 and 484 nm, with emission at 525 nm. In response to changes in redox 
conditions, roGFP exhibits reciprocal changes in intensity at the two excitation maxima (494), 
and its ratiometric characteristics render it insensitive to expression levels (495-497). RoGFP-2 
(Cyto roGFP) localizes primarily to the cytoplasm. RoGFP-1 (Mito-roGFP) was engineered to 
express GFP containing the pyruvate dehydrogenase E1subunit leader sequence for targeting to 
mitochondria (494). ADR-RES cells transfected with roGFPs were treated with 10 µM RTI-79 
and immediately analyzed by FACS with 400 nm and 488 nm lasers for excitation and 515 nm 
for emission. Oxidized and reduced roGFP assays were conducted by incubating cells in the 
presence of 25 µM H2O2 and 1 mM DTT, respectively. The oxidation state of roGFP was 




3.2.12 Confocal microscopy for subcellular localization of ROS 
ADR-RES ovarian carcinoma cells were infected with a baculovirus expressing a GFP-tagged 
recombinant protein (Bacman; Life Technologies) localizing to the mitochondria for 24 hours in 
the presence of RTI-79. Cells were then co-stained with CellROX (ROS indicator) and DAPI 
(nuclear stain) for 1 hour. Viable cells were immediately imaged under a confocal microscope. 
CellRox does not enter into organelles but remains in the cytoplasm and will react with ROS in 
the vicinity of their origin. 
 
3.2.13 Q-RT-PCR 
RNA was extracted from cells using Qiagen RNeasy Mini kit, catalog number 74106 and 
quantitated by Nanodrop fluorimeter. We utilized QuantiTect SYBR Green RT-PCR Master Mix 
(Mat. number 1026225) to perform RT and PCR on the same reaction. 
Commercially available QuantiTect Primer Assay gene specific primers were used on a 
Stratagene Mx3005P System that ran the following cycling parameters: Reverse transcription for 
30 min 50 C; PCR initial activation 15 min 95 C; followed by 40 cycles of denaturation 15 sec at 
94 C, annealing 30 sec 55 C, and extension 30 sec 72 C. Each RNA sample was amplified in 
triplicate and cycle thresholds (Ct) were determined automatically and delta Ct for each cell line 
were determined by subtracting the gene of interest Ct from the GAPDH Ct. Differences in delta 
Ct were determined between cell lines or treatment groups and converted to fold change. 
 
3.2.14 Western blots and antibodies 
For protein extraction, cells were solubilized in RIPA lysis buffer (Sigma Aldrich), 
supplemented with protease inhibitors (Sigma Aldrich), on ice for 20 min. 
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The detergent extracts were collected and centrifuged at 20,000 × g for 15 min at 4 C and then 
electrophoresed under reducing conditions by addition of Laemmli SDS-PAGE sample buffer 
and resolved by SDS-PAGE (BioRad). Western transfer of proteins and blocking of Hybond-
ECL (Amersham Biosciences) with 2% BSA were performed following manufacturers’ protocol. 
Immunoblotting with primary antibodies (1:1000) was followed by horseradish peroxidase 
conjugated anti-rabbit (1:1000) and detection using SuperSignal West Pico chemiluminescent 
substrate (Pierce, Rockford, IL). Antibodies: Actin: abcam cat#ab3280, Nrf2 (Nrf2): abcam cat# 
ab62352, NQO1: Cell Signaling Cat#3187, HMOX: Cell Signaling Cat #5853, BiP: Cell 
Signalling Cat#3177, Total IRE1alpha: Cell Signalling cat#3294, Total PERK: Cell Signaling 
cat# 5683, CHOP: Cell Signaling cat#2895, XBP-1s: Cell Signaling cat#12782, SYVN: Cell 
Signaling 14773, Phosph-PERK (1:500): Santa Cruz Biotechnology Cat#sc-32577, and Phospo-
IRE1 alpha pSer724: ThermoFisher cat# PA1-16923. 
 
3.2.15 Caspase 3/7 activity 
The assay was performed using Promega’s Caspase 3/7 Glo kits as per manufacturer’s 
instructions and imaged on a GE INCell Analyzer to detect fluorescent signal. Images were 
analyzed using the INCell Developer software to determine cell count. Values were averaged 
over the triplicates and SEM calculated. 
 
3.2.16 RNAseq 
RNA was extracted using Qiagen RNeasy miniprep kit from 1ml of cultures containing 
~1,000,000 cells. The samples were then depleted of ribosomal RNAs using the RiboZero kit 
from Epicenter. Adapters were the applied using the Illumina RNA-Seq kit. The samples were 
sequenced on an Illumina 2500 in single-end mode, collecting 10-15 million reads per sample. 
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3.2.17 Analysis of RNAseq data 
The reads were aligned to the human genome (build GRCh37.69) using Bowtie2 to produce 
SAM files (498). Cufflinks 2.2.1 (499) was used to calculate normalized FPKM values 
(Fragments Per thousand (K) nucleotides per Million reads) for each transcript in the annotation. 
Statistical analysis of differential expression was done using Cuffdiff 2.2.1 (499), which uses the 
Negative Binomial distribution to assess the significance of fold-changes between samples and 
assign p-values. The Benjamini-Hochberg procedure for multiple-tests correction was applied to 
calculate adjusted p-values. 
 
3.3 Results 
3.3.1 High throughput screening strategy and identification of rifabutin 
We found that rifabutin was highly synergistic with CHOP (cyclophosphamide, doxorubicin, 
vincristine, and prednisone) in drug-resistant NHL cells. This synergy was discovered by 
screening a highly diverse collection of approximately 50,000 drug-like molecules including the 
NIH Clinical Collection (www.nihclinicalcollection.com) against a CHOP-resistant NHL cell 
line (referred to as G3) in the presence of normally cytotoxic levels of CHOP and then counter 
screening the library against its CHOP sensitive parental line, ATCC CRL-2631 cells. The 
resistant G3 sub-cell line was derived from CRL-2631 through repeated on-off cycles of CHOP 
treatment, analogous to clinical therapy (83). The G3 cells were over 25 times more resistant to 
doxorubicin (DOX) (IC50 3.1 µM) compared to the parental CRL-2631 cells (IC50 0.12 µM). 
Following validation of screening hits, we prioritized the natural product-derived antibiotic, 
rifabutin, because of its potent synergy with CHOP and its lack of inherent cytotoxicity. 
Additionally, rifabutin has been used clinically for almost 25 years, is orally bioavailable, 
crosses the blood-brain barrier, and has excellent toxicological and pharmacological profiles. 
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3.3.2 Development of RTI-79 
We determined that the key structural characteristic for rifamycin synergizing activity and low 
cytotoxicity is the 3,4-[2-spiro-(isobutylpiperidinyl)-(1H)-imidazo] substitution at the 3,4 
position of the quinone (Figure 3.1A). For example, rifampicin with its hydroxyquinone (a 
hydroxy at the 4-position) and (4-methylpiperazin-1-yl)iminomethyl at the 3-position did not 
show appreciable synergy with DOX in the G3 cells (Figure 3.1B), nor was it cytotoxic on its 
own in primary human dermal fibroblasts (HDF cells) up to 80 µM (Figure 3.1C), though 
rifamycin SV with a hydrogen at the 3-position and a hydroxyl at the 4-position and rifamycin B 
with a hydrogen at the 3-position and carboxymethyloxy at the 4-position were cytotoxic alone 
(IC50 ~ 20 µM and 8 µM, respectively on HDF cells (Figure 3.1C)). This initial SAR pointed to 
the importance of the hydroxyquinonimine core of rifabutin for the synergy with DOX. A series 
of substitutions made to the hydroxyquinonimine, such as alkyl, aryl, amide, urea, or carbamate 
groups (Figure 3.1A) showed considerable variability in the DOX synergizing activity of the 
analogs (Figure 3.1A); with the substitution of a carbamate being the most potent. Improvements 
in solubility without losing activity were made by modifications at the ketone group at the 11-
position through conversion to a hydroxyl (RTI-175), amine (RTI-176), and imine (RTI-81). 
Hydroxyl or amine substitutions at the 11-position slightly decreased activity, as measured by 
the increase of the IC50 of DOX against G3 cells, compared to the ketone (RTI-79 vs RTI-175 
and RTI-176). Although imine substitution (RTI-81) showed good activity, it was unstable and 
converted to RTI-79 with a ketone group at the 11-position. The more stable imine derivative 
ketoxime (RTI-197) was also prepared but had decreased sensitizing activity. RTI-79, in 
particular, outperformed rifabutin by more than 6-fold in DOX-sensitization on G3 cells (Figure 
3.1B). Further, the in vivo toxicity and pharmacokinetics (PK) of RTI-79 were indistinguishable 
from rifabutin (see below).While the degree of synergy is impressive between rifabutin and 
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DOX, ratio checkerboard assays and combination index plots demonstrated that RTI-79 showed 
substantially more synergy with DOX as indicated by increased fractional activity at the ratios 
tested in G3 cells (between 5:1 and 10:1) (Figure 3.1D). As both DOX and rifamycins are known 
to use ROS as part of their mechanism of action, we continued to focus on understanding the 












Figure 3.1 Medicinal Chemistry is used to define SAR and discover RTI-79. (A) Chemical 
structures of rifabutin, and other commercially available rifamycins including rifampicin, and 
comparison with analog structures of RTI-44, RTI-79, RTI-81, RTI-175, RTI-176, and RTI-197. 
(B) Relative potency of rifamycin structures and analogs in combination with 0.5 µM DOX on 
G3 cells as determined by resazurin-based cytotoxicity assay at analog concentrations up to 80 
µM. (C) The relative lack of toxicity of rifamycin structures and analogs on primary human 
dermal fibroblast cells (HDF) as determined by resazurin-based cytotoxicity assay at analog 
concentrations up to 80 µM. Only rifamycin B and rifamycin SV show toxicity with IC50’s 
below 20 µM. (D) The combination index plot (also known as the Chou-Talalay plot) generated 
via Compusyn software showing the resulting combination index (CI) which offers a quantitative 
definition for synergism when CI < 1. Data for G3 cells and constant-ratio drug combinations of 
rifabutin: DOX at 10:1 or 5:1 (RFDX10 and RFDX5 respectively) and RTI-79: DOX at 10:1 or 
5:1 (RTDX10 and RTDX5 respectively) are plotted and virtually all data points indicate synergy 








3.3.3 RTI-79 has a broad in vitro spectrum of action 
When we evaluated the effects of RTI-79 on 10 NHL cell lines with variable degrees of DOX 
resistance (Table 3.1 and Figure 3.2a-j), we observed that the potency of DOX against these 
resistant cells was restored to levels active against sensitive NHL cell lines. For example, 10 µM 
RTI-79 reduced the DOX IC50 for the laboratory-derived G3 cells greater than 8-fold from 3.08 
µM to 0.44 µM (Table 1 and Supplementary 1a). Improvements in DOX susceptibility were also 
observed for patient-derived resistant NHL cell lines (500, 501); RTI-79 shifted the DOX IC50 of 
U-2932 cells from 1 µM to 0.22 µM. Of particular clinical importance is that DHL (WSU-
FSCCL, SU-DHL-6, SU-DHL10, and OCI-Ly19) and even THL (SU-DHL-4) (500, 502) cells 
responded to RTI-79, shifting their sensitivity to DOX to that observed for drug-sensitive NHL 
cells (Table 1 and Figure 3.2b-e). While all of the resistant NHL cell lines tested responded to 
RTI-79, only the relatively drug-sensitive cell lines HT and CRL-2631 did not show any 
statistically significant differences in sensitivity to DOX after the addition of RTI-79 (Table 1 
and Figure 3.2g, j). 
The liposome formulation of doxorubicin (DOXIL) is widely used as a second-line therapeutic 
for ovarian cancer. Unfortunately, irrespective of the selected treatment, ovarian cancer 
recurrence is very common and incurable for most patients (503); hence, any improvements in 
therapy would be extremely beneficial. We thus tested RTI-79 in combination with DOX in 5 
drug-resistant ovarian cancer cell lines including NCI/ADR-RES, the most well-studied and 
highly drug resistant ovarian cancer cell line ever reported (Table 1 and Figure 3.2k-o). RTI-79 
(10µM) shifted the NCI/ADR-RES DOX IC50 from over 187µM (504) to 0.23 µM (over 800-
fold improvement in potency) (Table 1 and Figure 3.2k). RTI-79 shifted the IC50 in resistant cell 
lines back to what is typically observed in sensitive cell lines. For example, the SK-OV-3 IC50 
shifted from 1.3 µM to 0.37 µM (3.5-fold) (Table 1 and Figure 3.2l), and the OVCAR-8 IC50 
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shifted from 0.38 µM to 0.14 µM (Figure 3.2m). Similar to what was observed for NHL, RTI-79 
showed the most potent effect in drug-resistant ovarian cancer cell lines. Furthermore, as with 
G3 NHL cells described above, ratio checkerboard assays and combination index plots indicated 
that both rifabutin and RTI-79 synergize with DOX in ADR-RES cells (Figure 3.2p). 
We found that RTI-79 is also effective in many other types of drug-resistant cancers, including 
uterine sarcoma, osteosarcoma, pancreatic cancer, and leukemia (Table 1 and Figure 3.2q-t). 
Moreover, RTI-79 is able to potentiate the activity of a variety of chemotherapeutics, including 
daunorubicin, epirubicin, vinblastine, etoposide, paclitaxel, and topotecan (Table 1 and 
Supplementary Fig 3.1w-c´). Indeed, RTI-79 was effective at enhancing the cytotoxicity of a 
























Figure 3.2 Spectrum of RTI-79 activity on various types of cancer cells lines and with  
 
                   multiple chemotherapeutics. (a-o, q-c´) Dose response curves visually depict all 
data summarized in Table 1. Cell lines are listed in the same order and show cell’s dose response 
to chemotherapy alone or chemotherapy plus RTI-79 as determined by resazurin blue 
cytotoxicity assay. Error bars represent SEM. (p) The combination index plot (also known as the 
Chou- Talalay plot) generated via Compusyn software showing the resulting combination index 
(CI) which offers a quantitative definition for synergism when CI < 1. Data for ADR-RES cells 
and constant-ratio drug combinations of hifalutin: DOX at 10:1 or 5:1 (RFDX10 and RFDX5 
respectively) and RTI-79: DOX at 10:1 or 5:1 (RTDX10 and RTDX5 respectively) are plotted 


































3.3.4 RTI-79 PK and toxicity profiles are equivalent to rifabutin 
To evaluate the PK of RTI-79 in comparison to rifabutin, both were given individually via oral 
administration to dogs at 9 mg/kg and plasma samples were collected over 48-hours. A 
maximum concentration (Cmax) of 1350 ± 450 ng/mL and 1182 ± 434 ng/mL was reached at 1.7 
± 0.6 and 1.3 ± 0.6 hours post dose with an average half-life of 26.3 ± 5.1 and 19.7 ± 0.8 hours 
for RTI-79 or rifabutin, respectively (Figure 3.3A). These data indicated that RTI-79’s PK 
characteristics are similar to rifabutin and thus sufficient for clinical use. RTI-79 has no overt 
toxicity in mice at high doses (250 mg/kg; 10-fold the dose used in efficacy studies [see below] 
or 5 times the human equivalent dose based on body surface area; BSA). After 3 weekly oral 
doses of RTI-79, all mice gained weight and no significant differences were observed after 
analysis of blood and serum for complete blood count (CBC) and manual differentials (Figure 
3.3B). Further, rats were given two daily doses of 500 mg/kg RTI-79 and there were no 
detectible differences in blood chemistry, CBC, or manual differential (data not shown). Finally, 
we determined that RTI-79 does not appear to exacerbate the known cardiotoxicity associated 
with DOX by giving both drugs in combination and evaluating body weight and CBCs in one 
study and heart function via echocardiograms, the most sensitive measure for cardiotoxicity, in a 
second study (Figure 3.3C-D). Histology was performed on all hearts that received 
echocardiograms (Figure 3.3E). We saw no significant differences between DOX-alone and 
DOX plus RTI-79 treatments at therapeutically-relevant doses in any of the measures. The 
ejection fraction and global and longitudinal strain showed no differences between the two 
regimens. Statistical differences in body weight, platelet counts, and heart rate (p<0.5) were 
detected between groups treated with DOX and DOX plus RTI-79 in comparison to saline-
treated mice (Figure 3.3C-D). Mild histologic changes were also present in both DOX-treated 
groups (Figure 3.3E). Together these data indicated that while the DOX dosing regimen caused 
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mild cardiotoxicity, RTI-79 does not worsen mild DOX cardiotoxicity when given concurrently 
in vivo. Thus, RTI-79 has desirable PK characteristics and is safe in vivo. The low toxicity 
observed for RTI-79 is consistent with its parent rifabutin molecule, which has an oral LD50 of 













Figure 3.3 PK and toxicity data for RTI-79. Data indicate that it has PK characteristics similar 
to rifabutin, is not toxic at high doses, and does not exacerbate or add to the known 
cardiotoxicity of DOX. (A) Plasma concentration of rifabutin and RTI-79 over time in male 
beagle dogs after oral administration of 9 mg/kg compound over a 48 hour time period. (B) 
Table of CBCs and manual differentials after administration of 3 weekly doses of high 
concentration (250 mg/kg) RTI-79 in mice indicating little change and lack of toxicity. Error 
bars represent SEM. (C) Mouse CBCs and weights after 6 weekly treatments of: saline, 7 mg/kg 
iv DOX given once weekly, or combination 7 mg/kg iv DOX given once weekly with 25 mg/kg 
RTI-79 given orally the same day and 24 hours post-DOX treatment. Error bars represent SEM. 
* indicates p<0.05 for saline treatment in comparison to both DOX and DOX+ 79. (D) 
Echocardiogram measurements after five weekly treatments of: saline, 7 mg/kg iv DOX, or 
combination 7 mg/kg iv DOX with 25 mg/kg oral RTI-79 given on the same day and 24 hours 
post-DOX treatment. Only heart rate is significantly affected (p<0.5) as indicated with “*”. (E) 
H&E stain of histological section of hearts from echocardiogram study. Analysis of sections 
show that 2 of 8 hearts that received DOX only treatment have single necrotic fibers with 
surrounding inflammation and macrophage (as indicated by the arrow); however, only 1 of 8 
hearts treated with DOX+RTI-79 show this feature. Necrotic fibers were not detected in saline 






3.3.5 RTI-79 efficacy in in vivo xenograft models of NHL and ovarian cancer 
We performed efficacy studies in mouse xenograft models of human DLBCL and ovarian cancer 
cells. Tumors were treated with saline, RTI-79 alone, chemotherapeutic alone (DOX, etoposide, 
or DOXIL), or RTI-79 in combination with drug. In all cases, there was a dramatic reduction in 
tumor growth when combination therapy was given. For example, in mice with tumors derived 
from the DHL cell line WSU-FSCCL, clinically relevant levels of DOX had little effect on 
tumor growth. However, DOX + RTI-79 (25 mg/kg po) stopped tumor growth (p=0.0034 for 
DOX vs DOX+ RTI-79) (Figure 3.4a-b). Similarly, there was a significant reduction in growth 
of WSU-FSCCL tumors with the combination of etoposide (a component of ICE salvage 
chemotherapy) and RTI-79 compared to etoposide alone (p = 0.02) (Figure 3.4c-d). Mice 
harboring ovarian cancer xenografts derived from NCI/ADR-RES and SK-OV-3 (another well-
studied drug-resistant ovarian cancer cell line) cells were given weekly DOXIL cycles with and 
without RTI-79 treatment at 24 and 48 hours post DOXIL. Both ovarian cancer xenograft 
models showed efficacy of RTI-79 + DOXIL over DOXIL alone (p= 0.0004 and 0.0002 
respectively) (Figures 3.4e-h). Again, DOXIL-alone treatment had minimal effect on tumor 
growth for ADR-RES xenografts and no effect on SK-OV-3 xenografts. However, the addition 
of RTI-79 to DOXIL therapy stopped tumor growth in ADR-RES xenografts and severely 
limited it for SK-OV-3 xenografts. Furthermore, the activity of rifabutin against xenografts is 
statistically inferior to the addition of RTI-79 (p=0.01), and rifabutin treatment is not 





Figure 3.4 RTI-79 in combination with standard chemotherapies is effective in treating 
 
                  mouse xenograft models of NHL and ovarian cancer in 6-8 week old female  
 
                  mice. Two-tailed Student’s t-test was run to evaluate statistical significance between 
groups. Samples were unpaired. (a-b) SCID mice were injected with 1 X 107 WSU-FSCCL cells. 
After one week tumors were an average size of 370 mm3 and treatments began. Arms included 
saline (Day 0 and Day7), i.v. 3.3 mg/kg DOX (Day 0 and Day7), oral 25 mg/kg RTI-79 (Day 0, 
1, 7, and 8), and combination DOX (Day 0 and 7) with RTI-79 (Day 0, 1, 7, and 8). C d.) WSU-
FSCCL xenografts were implanted into SCID mice and treated 11 days later when tumor volume 
was approximately 165 mm3. Three total treatments were given weekly starting at Day1. Arms 
included: saline, 12 mg/kg etoposide given on days 1, 2, and 3 of each week, 25 mg/kg RTI-79 
given on days 1, 2, and 3 of each week, or etoposide plus RTI-79. (e-h) In the third and fourth 
study, nude mice were injected with either 1 X 107 ADR-RES cells and treated 9 days later when 
tumor volume was approximately 90 mm3 (e, f) or 1 X 107 SK-OV-3 cells and treated 3 weeks 
later when tumor volume was approximately 100 mm3 (g, h). Arms included: saline, 7 mg/kg 
DOXIL iv given on Day 1 of each week, 25 mg/kg oral RTI-79 given on days 2 and 3 of each 
week, a combination of DOXIL and RTI-79, or a combination of DOXIL and rifabutin. Error 
bars represent SEM. 
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3.3.6 RTI-79 overcomes drug-resistance through a rapid increase in superoxide and 
hydrogen peroxide 
Many different approaches were used to determine the mechanism of action (MOA) of rifabutin 
and RTI-79 in sensitizing drug resistant cancer cells to standard chemotherapy. First, we 
performed RNAseq to evaluate the transcriptome changes in resistant (G3 and ADR-RES) and 
sensitive (CRL2631 and OVCAR8) cell lines with and without treatment with RTI-79 for 1 hour 
and 6 hours. We found that at these time points, there were few transcripts that showed large 
changes due to treatment (Figure 3.5A). We found that overexpression of the drug pump ABCB1 
(P-gp) was associated with chemoresistance in NCI/ADR-RES and G3 cells. P-gp was 
upregulated over 9.3-fold in the resistant G3 cells as compared to the more sensitive CRL-
2631cells, and P-gp was upregulated 89-fold in the resistant NCI/ADR-RES cells as compared to 
the more sensitive OVCAR-8 cells (Figure 3.5B). Indeed, the overexpression of P-gp in the 
NCI/ADR-RES cell line is already well-documented (506). Second, we determined that RTI-79 
and rifabutin are substrates for P-gp (Figure 3.5C), and they can prevent calcein-AM efflux from 
ADR-RES cells, a measure of drug pump activity (Figure 3.5D). In addition, RTI-79 caused 
increased DOX accumulation in G3 and ADR-RES cells (Figure 3.5E-F). However, inhibition of 
the P-gp drug pump is unlikely to be a primary mechanism, as P-gp levels were not elevated in 
all cell lines where we observed RTI-79 chemosensitizing activity (Figure 3.5G).  
Finally, other ansamycins such as geldanamycin are known to inhibit HSP90 and prevent 
expression of HSP90 targets such as RAF-1, but we did not detect any changes in RAF-1 
expression in rifabutin-treated cells. Moreover, rifabutin and RTI-79 did not bind to purified 





Figure 3.5 RTI-79 overcomes chemoresistance associated with overexpression of drug  
 
                   pumps and results in elevated intracellular drug concentrations. (A) RTI-79 
induces a little change in the transcriptome after 1 and 6 hours of treatment in G3 cells based on 
RNA-Seq analysis. (B) ABCB1/MDR1/P-glycoprotein mRNA expression in drug sensitive 
(CRL-2631 and OVCAR-8) and resistant (G3 and NCI/ADR-RES) cell lines indicates its 
overexpression is associated with resistance. (C) Stimulation of P-gp ATPase activity in P-gp 
Glo assay by rifabutin, RTI-79, and known Pg-p substrate verapamil indicates that RTI-79 is a 
substrate for P-gp. (D) Inhibition of Calcein AM efflux by RTI-79, rifabutin, rifampicin, and 
known inhibitor verapamil indicates that RTI-79 inhibits efflux. (E, F) Increased intracellular 
DOX fluorescence inside ADR-RES cells (E) or G3 cells (F) after treatment with RTI-79. From 
left to right: live micrograph of cells treated with 5 µM DOX for 2 hours; live micrograph of 
cells treated with 5 µM DOX in combination with 5 µM RTI-79 for 2 hours; quantitation of 
relative light units of intracellular DOX fluorescence over 2 hours live imaging time for cells 
treated with DOX only, or DOX plus RTI-79. (G) Relative P-gp mRNA levels in various cancer 
cell lines compared to OVCAR8 ovarian cancer cells as determined by q-RT-PCR. Note that y-



















































2 0 0 0 0 0
4 0 0 0 0 0

























C a lc e in  A M  e f f lu x









V e ra p im il
R ifa b u tin
R ifa m p ic in






































































































5 uM Dox 5 uM Dox  
+ 5 uM RTI-79




























Figure 3.6 Rifabutin and RTI-79 are not effective inhibitors of HSP90. (A) Inhibition of 
HSP90 by known inhibitor geldanamycin (0.5 µM) leads to reduced RAF-1 protein as detected 
by western blot and densitometry, but up to 20µM rifabutin does not. (B) Inhibition of HSP90A 
and HSP90B refolding by known inhibitor 17-AAG causes changes in Tm, but rifabutin and 
RTI-79 do not. BSA was included as a control to show specificity of 17-AGG for HSP90. Error 
bars represent SEM. Further, the tip of the geldanamycin ansa ring, which has a carbamate, binds 
near the bottom of the Hsp90 pocket and makes a high density of van der Waals contacts [1]. 
The carbamate amino group makes a critical hydrogen bond to one of the Asp93 side chain 
oxygen atoms. Note that RBT and RTI-79 have no carbamate at this position to make these 












Consistent with other studies that report the association of low ROS levels with resistance, basal 
ROS levels in the drug-resistant G3 and NCI/ADR-RES cells were much lower (13 and 3.3-fold 
respectively) than basal ROS levels of their respective drug-sensitive parental lines, CRL-2631 
and OVCAR-8 (Figure 3.7A). Treatment of the cells with RTI-79 dramatically increased ROS in 
all cancer cells tested, but paradoxically not in primary fibroblasts (HDF cells). For instance, 
RTI-79 increased ROS over 23-fold in G3 cells and 12.7-fold in NCI/ADR-RES cells, as 
measured with the CellROX ROS indicator (Figure 3.7B). RTI-79 also increased intracellular 
ROS as measured by an oxidation sensitive GFP construct, as treatment resulted in increases of 
emission spectra ratios for both cytoplasmic and mitochondrial GFP (Figure 3.7D). Further, 
ROS-oxidized CellROX primarily co-localized to mitochondria based on confocal microscopy, 
which showed that the red CellROX fluorescence co-localized with a mitochondrial GFP-tagged 
recombinant protein (Figure 3.7C). Induction of ROS was rapid, e.g. in as little as 10 minutes in 
G3 cells (Figure 3.7D). Such rapid induction indicates that this initial response does not involve 
transcription or translation which would likely require hours. As determined by ROS species-
specific dyes, we observed a greater than 12-fold increase in intracellular superoxide levels in 
RTI-79 treated G3 cells, a two fold increase in hydrogen peroxide, and no changes in hydroxyl 
radicals (Figure 3.7E). This is consistent with redox cycling of quinone-containing compounds 
(such as rifamycins) that are known to generate primarily superoxides (507, 508). We found that 
either by dose-response or by comparing compounds within the series, ROS induction was 
highly correlated to synergy with DOX. For example, RTI-79 generated higher levels of ROS 
compared to rifabutin. Moreover, rifampicin does not produce ROS and does not synergize with 
DOX to reverse drug resistance (compare Figure 3.7F with Figure 3.1B). RTI-79 was the most 
potent synergizer and produced up to 10 fold more ROS, compared to rifabutin at the same dose. 
To further demonstrate the correlation between synergy and ROS levels, when the anti-oxidants 
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quercetin and luteolin (509) were added they were able to reduce RTI-79-induced ROS by over 
17-fold with quercetin and up to 3-fold with luteolin (Figure 3.7G-H). Most importantly, altering 
ROS levels with these compounds concomitantly alters RTI-79 + DOX induced cytotoxicity; 
quercetin and luteolin are protective against RTI-79 + DOX induced cytotoxicity in G3 and 
ADR-RES cells (Figure 3.7I-G). For example, the addition of 1 µM RTI-79 to DOX in G3 cells 
kills virtually all cells, but the addition of quercetin rescues up to 60% of the cells (Figure 3.7I). 









Figure 3.7 RTI-79 overcomes chemoresistance associated with low ROS by inducing a  
 
                   rapid increase in superoxide and hydrogen peroxide, but can be quenched with  
 
                   antioxidants luteolin and quercetin. (A) Basal and RTI-79 (10 µM) induced ROS 
in NHL, ovarian cell lines, and primary fibroblasts as determined by CellROX and FACs. (B) 
Confirmation that ROS are indeed generated by RTI-79 by utilizing an assay independent of 
fluorescent dye up-take e.g. a GFP Biosensor. The GFP Biosensor changes oxidation state after 
encountering ROS and/or RTI-79 (10 µM) both in the cytoplasm and the mitochondria. DMSO 
was utilized as a no treatment control. DTT (100 µM), a known ROS scavenger was utilized to 
antagonize RTI-79. (C) Confocal analysis indicates that ROS originates primarily at the 
mitochondria in NCI/ADR-RES cells. (D) RTI-79 (10 µM) induces ROS in as little as 5 minutes 
and ROS remains sustained over 60 minutes in G3 cells. (E) ROS species specific dyes for 
superoxide, hydrogen peroxide, and hydroxyl radicals indicate that RTI-79 primarily produces 
superoxide in G3 cells. (F) Dose-dependent quantitation of ROS (as measured by CellROX 
imaging) with RTI-79, rifabutin, and rifampicin in G3 and ADR-RES cells. (G-H) The addition 
of anti-oxidants quercetin and luteolin reduce RTI-79-induced ROS levels in G3 cells (G) and 
ADR-RES cells (H). (I-J) The addition of antioxidants quercetin (100 µM) and luteolin (50 µM 
in G3 cells and 100 µM on ADR-RES cells) reduce RTI-79 (1 µM) + DOX induced cytotoxicity. 





3.3.7 Cancer cells cannot respond to RTI-79-induced ROS because of the inhibition of Nrf2 
Activity 
Normally, ROS production is controlled by the induction of the antioxidant response system 
regulated by Nrf2 (510). Review of our transcriptome data indicated that there was no 
antioxidant response as a set of 38 well-studied Nrf2 targets and their FPKMs were evaluated 
with statistical comparisons of p-values and adjusted q-values in CRL-2631, G3, OVCAR-8, and 
ADR-RES cells (Figure 3.8A). While, we saw induction of the Nrf2 targets NQO1 and HMOX1 
by q-RT-PCR in as little as 6 hours when cells were treated with tBHQ or Menadione (known 
antioxidant response generators), this response was not seen in cells treated with RTI-79 (Figure 
3.8B), despite the very large increases in ROS that we observe following RTI-79 treatment. 
Further, we saw a reduction in Nrf2 protein levels after treatment of G3 and ADR-RES cells 
with RTI-79 by 78% and 61%, respectively (based on Student’s t-test, p=0.007 and 0.03); tBHQ 
led to a 2-fold increase in Nrf2 protein levels (Figure 3.8C-D). We also saw a reduction in the 
downstream Nrf2 targets, HMOX, by 18% in G3 cells and 87% in ADR-RES cells, and NQO1 
by 64% in ADR-RES cells by Western blot (Figure 3.8C-D). When ROS levels are low, Nrf2 
homeostasis is maintained in the cytoplasm via KEAP1 and ubiquitin-mediated degradation 
(511, 512). In efforts to understand the observed loss of Nrf2, we investigated SYVN1 (Hrd1) as 
it is an E3 ubiquitin ligase that interacts directly with Nrf2. Activation of the IRE1a-XBP1 arm, 
one of the 3 major pathways of the unfolded protein response (UPR), transcriptionally 
upregulates SYVN1 by approximately 2-fold in liver cirrhosis, resulting in enhanced Nrf2 
ubiquitination, degradation, and attenuation of the Nrf2 signaling pathway (513). We find that 
RTI-79 increases SYVN1 expression by approximately 2 to 4-fold over time in both G3 and 
ADR-RES cells (Figure 3.8E). Again, the addition of quercetin and luteolin antagonized RTI-79-





Figure 3.8 RTI-79 does not induce antioxidant response and inhibits Nrf2 activity. (A) 
Table of 38-known Nrf2 target genes evaluated by RNA-Seq after 1 and 6 hours treatment with 
RTI-79. (B) q-RT-PCR confirms the lack of antioxidant response with RTI-79 treatment: fold 
change in HMOX and NQO1 mRNA at 6 and 24 hours in G3 and ADR-RES cells after 
treatment with RTI-79 (10 µM) and known anti-oxidant response inducers tBHQ (50 µM) and 
menadione (50 µM). (C) Representative blots showing that treatment of G3 and ADR-RES cells 
with 10 µM RTI-79 for 16 hours results in decreased Nrf2 and HMOX protein levels by western 
blot analysis. ADR-RES cells also show decreased NQO1 protein levels after RTI-79 treatment. 
(G3 cells did not have detectable NQO1 protein levels by Western blot). The known Nrf2 
stabilizer, tBHQ (50 µM) was used as a control (D) Average densitometric quantification of 
western blots for each cell line and treatment group normalized to actin concentration. The graph 
represents the average of 3 independent experiments. (E) Treatment of G3 and ADR-RES cells 
with 10 µM RTI-79 increases the mRNA expression of SYVN1 a known E3 ubiquitin ligase that 
interacts directly with Nrf2. The addition of antioxidants quercetin (100 µM) and luteolin (200 






3.3.8 RTI-79 induces UPR in drug resistant cancer cells 
Sustained ROS production has been linked to ER stress and the UPR (514). We utilized our 
transcriptome data and performed Generally Applicable Gene-set Enrichment (GAGE) and 
evaluated the GO term “response to unfolded protein” (GO:0006986) representing 157 genes. 
It was significantly enriched for differential expression (p<0.05) in all the cells (2631, G3, 
OVCAR8, and ADR-RES) at both 1 and 6 hour time points (data not shown). We tested this 
concept further by evaluating transcripts by q-RT-PCR. The addition of 10 µM RTI-79 results in 
increased expression of DDIT3/CHOP (up to 5-fold) and HSPA5A/BiP (up to 4-fold), and 
minimally increased expression of ATF4 mRNAs in both G3 and ADR-RES cells at various time 
points between 4 and 24 hours (Figure 3.9A-B). Dynamic and temporal changes in expression 
are known to occur based on the duration of stress (515). The addition of quercetin or luteolin 
antagonized the increased expression levels in ADR-RES cells at 8 hours of RTI-79 treatment 
but not necessarily in G3 cells (Figure 3.9C) indicating that reduction of RTI-79-induced ROS 
dampens the UPR response. RTI-79 treatment also resulted in increased protein expression of the 
IRE1a-UPR associated proteins (p-IRE1a, HSPA5A/BiP, and XBP1-s) at 8 and 16 hours (Figure 
3.9D-E), but not p-PERK (Figure 3.9E). As might be anticipated with the activation of the p-
IREa and XBP1-s arm of the UPR pathway, SYVN protein expression was also increased with 
the addition of RTI-79. RTI-79-induced expression of these proteins was also antagonized by the 
addition of quercetin or luteolin in ADR-RES cells (Figure 3.9D-E), again indicating that 
reduction of ROS dampens the UPR response. In addition, we observed that RTI-79 treatment 
resulted in increased total cellular ubiquitination of proteins, as would be anticipated for 
compounds that induce UPR (Figure 3.9F). However, RTI-79-induced UPR does not trigger 
apoptosis as it is not toxic when used alone. Indeed, CASP3 cleavage in G3 cells is not induced 
by RTI-79 alone (Figure 3.9G). When both RTI-79 and DOX are used together, we observe 
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CASP3 cleavage (Figure 3.9G) and cytotoxicity (Figure 3.1B). We propose that RTI-79 + 
chemotherapeutic induces chronic UPR and apoptosis. Hence, we propose a model (Figure 3.9H) 
in which ROS is rapidly induced by direct redox cycling of RTI-79, which results in UPR and 
SYVN1 induction. SYVN1, in turn, downregulates the Nrf2 pathway causing a state of oxidative 










Figure 3.9 RTI-79 induces UPR. (A-C) The addition of 10 µM RTI-79 induces the expression 
of genes associated with UPR in both G3 (A, C) and ADR-RES cells (B-C) over 4-24 hours. (C) 
The addition of antioxidants quercetin (100 µM) and luteolin (200 µM) antagonizes RTI-79 
induced gene expression at 8 hours. (D-E) Addition of RTI-79 induces the expression of proteins 
associated with UPR in both G3 and ADR-RES cells. Addition quercetin (100 µM) and luteolin 
(50 µM) antagonizes RTI-79 induced protein expression. (F) The addition of 10 µM RTI-79 to 
G3 and ADR cells results in increased total cellular ubiquitination after 4 hours. 100 nM Velcade 
was used as an inhibitor of the proteasome and a control for increased ubiquitination. (G) RTI-79 
alone does not increase caspase-3 activity (a measure of apoptosis) as determined by Caspase 
Glo 3/7 assay. G3 Cells were treated with compounds and then imaged to determine the ratio of 
the total number of cells over the number that are positive for Caspase 3 activity. (H) Model for 
RTI-79 mechanism of action. RTI-79 undergoes redox cycling to produce superoxide. Increased 
ROS induces UPR and activation of SYVN1 which in turn lead to increased ubiquitination of 
total cellular proteins and Nrf2. Loss of Nrf2 leads to the absence of the antioxidant response. 
When only RTI-79 is present the cell is able to reach homeostasis, but when DOX or another 
chemotherapeutic is present in combination, the cells become sensitized, activate Caspase 3 and 





Today, most cancer deaths are the result of recurrence, a situation where a cancer returns after 
remission. Often recurrent cancer will have either reduced or completely lost sensitivity to 
chemotherapy. There are currently no drugs that specifically target drug-resistant cancers. We 
have developed a novel and potent compound that reverses drug resistance for a number of 
cancers. RTI-79 is not designed to be a cancer drug, per se, but a versatile new compound that 
sensitizes cancer cells to existing approved cancer drugs without adding any new toxicity. Here 
we are able to demonstrate that low (10 µM), non-toxic concentrations of rifabutin and RTI-79 
are very effective at synergizing with chemotherapeutics by generating high levels of 
intracellular ROS in resistant cancer cells. 
Elevated levels of ROS are common in cancer cells, and many chemotherapeutics, including 
DOX, increase the levels of ROS as part of their mode of action. We show, in agreement with 
other studies, that a number of drug-resistant cancer cells have significantly lower levels of ROS. 
Figure 3.7A shows that basal ROS levels in the drug-resistant G3 and NCI/ADR-RES cells were 
much lower than basal ROS levels in their respective drug-sensitive parental lines, CRL-2631, 
and OVCAR-8. This is believed to occur through modifications of their complex, and not 
entirely understood, antioxidant response systems. Low ROS likely gives cancer cells a selective 
advantage for survival in the face of chemotherapy. We have demonstrated that for many cancers 
there is a direct correlation between ROS levels in the cell, and sensitivity to chemotherapy 
(Table 3.1 and Figure 3.7A, G-J). The higher the ROS levels, the more sensitive the cancer cell 
is to chemotherapy. As examples, CRL-2631 have about 13-fold higher ROS and are about 25-
times more sensitive to DOX than G3 cells, and OVCAR-8 have about 3.3-fold higher ROS and 
are about 490 times more sensitive than NCI/ADR-RES cells. 
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When we increase ROS levels with small molecules that generate ROS, we see significant 
increases in their sensitivity (Figure 3.7A). RTI-79 increased ROS over 23-fold in G3 cells and 
12.7-fold in NCI/ADR-RES cells. However, this can be reversed with common antioxidants 
albeit at relatively high levels (Figure 3.7G-H). Importantly, the changes in ROS correlate with 
RTI-79-induced sensitivity to chemotherapy (Figure 3.7I-J). Rifabutin and RTI-79 are members 
of a class of quinones that are known to be producers of ROS through redox cycling performed 
by reductases. What distinguishes RTI-79 from the other quinones, and makes it more potent and 
effective, is the fact that it also triggers the UPR (Figure 3.9A-E), which leads to increased 
ubiquitination (Figure 3.9F) and ultimately to the dysregulation of Nrf2 in the resistant cancer 
cells (Figure 3.8). Consequently, the cancer cells can no longer respond to increases in ROS by 
augmenting their antioxidant response. In contrast to other ROS generators (like tBHQ and 
menadione), RTI-79 displays a combination of high levels of ROS (Figure 3.7), reduction of 
Nrf2 levels (Figure 3.8), and potent ability to synergize with DOX (Figure 3.1, Table 3.1, and 
Supplementary Figure 3.1). 
One major concern was that increased ROS would also lead to toxicity in normal cells. That was 
not the case, as we did not see elevated ROS or cytotoxicity in primary fibroblasts (Figure 3.1C 
and 3.3A). In addition, we tested whether RTI-79 would increase DOX-induced cardiotoxicity. 
Mice treated either with DOX alone or with a combination of RTI-79 and DOX were evaluated 
by a number of different tests, including echocardiograms. Although mice in the DOX-only 
group demonstrated minimal histologic changes following administration of DOX, our results 




RTI-79 has essentially the same desirable pharmacology as rifabutin. For example, dog PK 
studies show similar plasma concentration (1350 ± 450 mg/mL) and half-life (26.3 ± 5.1 hours) 
at 9 mg/kg (Supplementary Figure 3.4a). In vivo efficacy studies with drug-resistant double-hit 
lymphoma and ovarian cancer xenograft tumors showed that RTI-79 was able to re-sensitize 
both of these cancers to the standard of care therapeutics including DOX, DOXIL, and etoposide 
(Figure 3.4). Most significant was the potent efficacy at relatively low doses (25 mg/kg) of RTI-
79. 
Further, our in vivo efficacy studies with RTI-79 predict a positive clinical outcome. First, we 
began treatment on actively growing tumors as this approach is more predictive of clinical 
potential compared to beginning treatment before tumor growth (516, 517). We also clearly 
surpass the 40% threshold of tumor reduction to indicate predictive clinical outcome (518). 
Finally, we show efficacy in xenograft models with multiple cancers (518). Hence, these 
preclinical models highly suggest that our observations will translate to clinical efficacy, and 
indicate that RTI-79 would be successful in trials of drug-resistant ovarian cancer and NHL, 
including DHL and THL. 
RTI-79’s utility in treating DHL and THL is particularly exciting and significant. Up to 78% of 
Burkitt’s and 12% of all DLBCL patients have DHL or THL (519). These patients often present 
with poor prognostic parameters despite aggressive treatments (520). It is remarkable that many 
DHL and THL have overexpression of BCL6. BCL6 overexpression is able to inhibit the normal 
increases in ROS levels and apoptosis that occur in response to chemotherapeutic agents, most 
likely by enhancing the antioxidant response (521). Hence it is tempting to speculate that RTI-79 
might be able to override the ability of BCL6 to inhibit increases in ROS as RTI-79 would 
overcome the enhanced activity of the antioxidant response system by degrading Nrf2. The 
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combination of RTI-79-induced increases in ROS and antagonism of anti-oxidant systems would 
cause the cell to become sensitized to oxidative stress-inducing chemotherapeutics. Thus, it 
might be efficacious to treat cancers that overexpress BCL6 as part of their resistance 
mechanism. Interestingly, BCL6 is also a negative prognostic indicator for ovarian cancer (522). 
Such a wide spectrum of action indicates that RTI-79 might be used clinically in multiple drug 







































OVERALL CONCLUSION AND FUTURE DIRECTION  
 
4.1 Research summary 
We have discovered that drug-resistant lymphoma and ovarian carcinoma cell lines have a lower 
oxidative state (ROS; reactive oxygen species) and increased expression of anti-oxidant Nrf2 
than their drug-sensitive counterparts. In normal cells during oxidative stress, Nrf2 upregulates 
G6PDH providing reducing equivalents (NADPH) for the maintenance of a pool of reduced 
mitochondrial glutathione (GSH) to balance the redox state, which has a crucial role in cellular 
signaling and antioxidant defenses (415-417, 442, 443, 523-525). Evidence emerging from 
diverse systems indicates that oxidative stress activation of Nrf2 upregulates G6PDH expression 
(442, 443), which generates reducing equivalents (NADPH) to increase glutathione (GSH) 
production through the pentose phosphate shunt. GSH scavenges ROS, thus reducing the redox 
state. (415, 442, 443, 446, 526-536). We showed that a more reduced intracellular state promotes 
resistance to chemotherapeutics. Based on published literature and our studies, we propose that a 
lower oxidative state in drug-resistant cells is caused by higher expression of anti-oxidant Nrf2 
and glucose-6-phosphate dehydrogenase (G6PDH) activities. 
To study drug resistance, acquired chemoresistant cell line models were generated by repeated 
on-off exposures of chemosensitive diffuse large B-cell lymphoma cells to increasing 
concentrations of doxorubicin-based chemotherapeutics (82, 83), similar to clinical CHOP 
chemotherapy protocols in patients. Employing the chemoresistant lymphoma cells in a high-
throughput screen, we discovered that a rifamycin (Rifabutin) reversed resistance to the 
chemotherapy cocktail, CHOP. Rifabutin on its own had no cytotoxicity but in the presence of 
CHOP caused cytotoxicity in resistant cells. Rifabutin acted to increase superoxide (O2-) and 
decrease Nrf2 expression in multiple drug-resistant cancer cell types.  
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We have created a novel non-toxic rifamycin derivative (RTI-79) from the parent rifabutin 
molecule that acts as a potent chemosensitizer in multiple types of cancer cells. RTI-79 reverses 
drug resistance in multiple types of cancers, including lymphoma and ovarian, breast, and 
prostate carcinomas. RTI-79 has little or no toxicity on its own but increases the sensitivity of 
chemoresistant cancers to a broad range of chemotherapeutics. RTI-79 has also shown great 
success in animals; in combination with doxorubicin-based chemotherapies, it neither 
significantly repressed lymphoma and ovarian carcinoma growth without increasing the side 
effects of medications nor adversely affect healthy cells. RTI-79 acts to increase the oxidative 
state in chemoresistant cancer cells by generating superoxide (O2-) and downregulating the Nrf2 
signaling pathway. The source of the rapid induction of O2- could be the direct oxidation of RTI-
79 as rifamycins have been reported to cause ROS production (493).  
 
4.2 Role of the mitochondrial unfolded protein response (UPRmt) in drug resistance 
In chapter III we showed that RTI-79 treatment results in increased total cellular ubiquitination 
of proteins. Our Protein mass spectrometry (MS sequence) data from a gel prep also revealed 
that RTI-79 increases the ubiquitination state of several mitochondrial-associated proteins (Table 
4.1). The mitochondrial unfolded protein response (UPRmt) has been recognized as a regulator 
of a mitochondrial retrograde signaling cascade that affects gene expression in the nucleus in 
mammals (537-539). UPRmt retrograde signaling has recently been implicated in cell survival 
and drug resistance, potentially by upregulating Nrf2 antioxidant defenses (538, 540). However, 
unlike the ER-associated UPR, the mechanisms behind the signal transduction cascade leading to 
mitochondrial UPR are not as well understood. One hypothetical chemoresistance mechanism is 
that the stress caused by repeated exposures to chemotherapeutics may select for cancer cells that 
have activated UPRmt caused by upregulated expression of the mitochondrial chaperones, 
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mtHSP70[mortalin], HSP60, and HSP40[DnaJ] (537, 541). It was of our interest that RTI-79 
increased the ubiquitination state of HSP70mt (mortalin) known to play role in the UPRmt 
(Table 4.1). The UPRmt chaperone, mtHSP70 [mortalin], is a key player in mitochondrial stress 
response, aging, and programmed cell death (542-544). Overexpression of mortalin extends 
lifespan in human cells and the nematode C. elegans, indicating a protective function in vitro and 
in vivo (545-547). Reduction of mortalin results in alterations in mitochondrial morphology, 
impaired mitochondrial membrane potential, and increased cellular levels of ROS (545). Indeed, 
we have detected increased expression of canonical UPRmt chaperones and Nrf2 in 
chemoresistant cells, and RTI-79 increased the ubiquitination state and decreased expression of 
UPRmt chaperones, along with increased ROS and sensitivity to chemotherapeutics. We believe 
that RTI-79 affects one or more ubiquitin-conjugating enzymes in mitochondria to increase the 
ubiquitination state of UPRmt chaperones thus destabilizing and decreasing mitochondrial 
retrograde signaling that drives upregulation of Nrf2/G6PDH/GSH. 
We believe this is significant since activation of the UPRmt mediates retrograde signaling, in 
which mitochondria have the ability to alter nuclear gene expression (548, 549). UPRmt is 
unique from the better understood UPR of the endoplasmic reticulum and has a potential impact 
on chemoresistant disease (550). The UPRmt is believed to compensate for metabolic 
dysfunction by stimulating retrograde communication through transcriptional regulators, such as 
NFκB, cAMP response element-binding protein (CREB), CCAAT-enhancer-binding protein 
homologous protein (CHOP), and nuclear factor of activated T cells (NFAT), to modulate gene 
expression to adapt mitochondria function to promote recovery and function to resolve the stress 
(539, 551, 552). In yeast, an optimal redox defense system appears to be an important outcome 




Table 4.1 RTI-79 increases the ubiquitination state of several mitochondrial-associated  
 
                  proteins. 
 
Protein Function 
ATP synthase, O subunit H+ transporting, mitochondrial F1 complex, 
(oligomycin sensitivity conferring protein) 
ATP synthase, alpha subunit H+ transporting, mitochondrial F1 complex 
Solute carrier family 25  Mitochondrial carrier; adenine nucleotide 
translocator, member 5 
Glyceraldehyde-3-phosphate dehydrogenase  Maintains the redox potential across the inner 
mitochondrial membrane in glycolysis 
Voltage-dependent anion-selective channel 
protein 1 (VDAC1) 
A protein of the outer mitochondrial 
membrane of eukaryotes forms a voltage-
dependent anion-selective channel (VDAC) 
that behaves as a general diffusion pore for 
small hydrophilic molecules 
Voltage-dependent anion-selective channel 
protein 3 (VDAC3)  
A protein of the outer mitochondrial 
membrane of eukaryotes forms a voltage-
dependent anion-selective channel (VDAC) 
that behaves as a general diffusion pore for 
small hydrophilic molecules 
Heterogeneous nuclear ribonucleoprotein 
A2/B1  
Mitochondrial stress-mediated transcription 
activation of nuclear target genes 
Heterogeneous nuclear ribonucleoproteins 
C1/C2  
Play a role in the early steps of spliceosome 
assembly and pre-mRNA splicing. 
Heterogeneous nuclear ribonucleoprotein H1 This protein is a component of the 
heterogeneous nuclear ribonucleoprotein 
(hnRNP) complexes which provide the 
substrate for the processing events  
Heterogeneous nuclear ribonucleoprotein K Regulates expression of uncoupling protein 2, 
UCP2, a member of a family of inner 
mitochondrial membrane ion carriers involved 
in a host of metabolic processes 
Heterogeneous nuclear ribonucleoprotein M  interaction with mitochondrial ribosomal 
protein S12, functions in mitochondrial 
mRNA localization for binding to ribosomal 
proteins 
Heterogeneous nuclear ribonucleoprotein U Promotes MYC mRNA stabilization. Binds to 
pre-mRNA. Binds to double- and single-







Table 4.1 Continued 
Heat shock 70kDa protein 9 (mortalin)  Anti-oxidant (grp75, mtHSP70) functions 
ranging from stress response, control of cell 
proliferation, and inhibition/prevention of 
apoptosis 
Peptidyl-prolyl cis-trans isomerase A  Protein folding 
Prohibitin  Anti-oxidant mitochondrial membrane protein 
– mitochondrial ubiquitin-proteasome 
pathway 
Elongation factor Tu (EFTu)  Mitochondrial protein translation 
Cofilin-1  Regulation of mitochondrial apoptosis 
Peroxiredoxin 1  Antioxidant – H202 detoxification – binds to 
p66Shc, preventing it from inducing 
mitochondrial H2O2 (ROS burst) 
 
Mitochondrial dysfunctions are an important determinant in conferring cancer cell resistance to 
certain chemotherapeutic drugs. However, the presence of mitochondrial dysfunctions involving 
the UPRmt retrograde signaling pathway may represent the “Achilles’ heel” for cancer cells, 
providing a basis for rationale development of therapeutic strategies to selectively kill cancer 
cells. Increases in the UPRmt canonical chaperones, HSP40, HSP60, and mtHSP70, that activate 
retrograde signaling is a new emerging paradigm driving chemoresistance. Thus, mitochondrial 
retrograde inhibitors may provide a new therapeutic opportunity in drug-resistant tumors with 
mitochondrial dysfunction. Along with this line, we have evidence (Figure 4.1) that RTI-79 is a 
novel chemosensitizing drug that targets mitochondrial UPRmt chaperones to downgrade 
retrograde signaling and promote oxidative stress. 
Based on our studies, we propose that drug-resistance is caused, in part, by activated 
mitochondrial retrograde signaling, which upregulates Nrf2 and its downstream antioxidant 
cascade, G6PDH/GSH (Figure 4.2). 
RTI-79 promotes chemosensitization by downregulating the Nrf2/G6PDH/GSH cascade via 













Figure 4.1 The hypothetical model in which RTI-79 targets mitochondrial UPRmt  
 
                   chaperones to downgrade retrograde signaling and promote oxidative stress. 
RTI-79 reverses drug resistance by downregulating the UPRmt, resulting in loss of CREB 












Figure 4.2 The hypothetical model in which UPRmt retrograde signaling drives the  
 















Figure 4.3 The hypothetical model in which RTI-79 targets downregulation of the UPRmt  
 
                   retrograde signal to reverse drug-resistance. RTI-79 induces 















The UPRmt can cause activation of retrograde signaling that drives upregulation of Nrf2 and 
G6PDH (Figure 4.2). More specifically, our preliminary data demonstrate that RTI-79 causes the 
following events in chemoresistant cells: (1) increased superoxide; (2) an increased 
ubiquitination state in canonical UPRmt chaperone proteins; (3) decreased expression of UPRmt 
chaperones; (4) decreased activation (ser133 phosphorylation) of the CREB mitochondrial 
retrograde signal mediator; (5) decreased Nrf2, G6PDH, and GSH (higher oxidative stress); and 
(6) increased sensitivity to multiple chemotherapeutics, including doxorubicin, etoposide, and 
cisplatin. 
Moreover, activated UPRmt retrograde signaling has been reported in the literature to upregulate 
MDR pumps (i.e., P-gp), and RTI-79 downregulated P-gp activity in drug-resistant cells. 
Additional support for our chemosensitization model, as we showed in chapter II, is that a 
G6PDH inhibitor (i.e. DHEA) induced O2- and increased the sensitivity of chemoresistant cells 
to CHOP. 
Our discovery that RTI-79 increased the ubiquitination state of canonical UPRmt chaperones is 
significant since several reports indicate a role for ubiquitination in regulating chaperone 
activities (554-556). First, the E3 ubiquitin ligase, CHIP, ubiquitinates the HSP70 chaperone 
(557). When HSP70 carries no client proteins, CHIP catalyzes its polyubiquitination and 
subsequent proteasomal degradation. Second, ubiquitination upon oxidative stress is not a 
random process to degrade the mass of oxidized proteins but concerns specific targeted 
ubiquitination of functional proteins, including chaperones (558). Third, the Ubiquitin-like 
protein 5 positively regulates chaperone gene expression in the UPRmt (559). Moreover, the 
ubiquitin-proteasome (UPS) and mitochondria systems are highly interdependent 
(Mitochondrion-UPS Axis) (560). The UPS is not only involved in the degradation of proteins 
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present in the mitochondrial outer membrane, but also of substrates derived from the inner 
membrane and matrix (561-563). 
Therefore, we hypothesize that RTI-79 targets the repression of UPRmt through the increased 
ubiquitination state/degradation of mitochondrial chaperones, which represses retrograde 
signaling and causes decreases in Nrf2/G6PDH/GSH antioxidant activities in chemoresistant 
cells leading to reversal of drug resistance (Figure 4.3). Downstream signaling steps and 
transcriptional regulation of the mammalian UPRmt remain not well understood. Although we 
have gathered substantial preliminary data implicating a role for UPRmt in reversal of drug 
resistance, more study is needed to more fully understand the regulation of the UPRmt and how 
downstream retrograde signals promote drug resistance. Along these lines, we believe RTI-79 is 
a novel anti-cancer agent that targets the UPRmt and can be a useful tool to probe the 
mechanism of action of the UPRmt in cancer chemoresistance.  
 
4.3 RTI-79-mediated chemosensitization in drug-resistant cancer cells  
In Chapter III, we showed that that low (10 µM), non-toxic concentrations of RTI-79 synergizes 
with chemotherapeutics by generating high levels of intracellular ROS (predominantly 
superoxide) in resistant cancer cells. RTI-79 acts to increase the oxidative state in chemoresistant 
cancer cells by generating superoxide. RTI-79 also triggers the UPR, which leads to increased 
ubiquitination and ultimately to the dysregulation of Nrf2 in the resistant cancer cells. 
Consequently, the cancer cells can no longer respond to increases in ROS by augmenting their 
antioxidant response. In contrast to other ROS generators (like tBHQ and menadione), RTI-79 
displays a combination of high levels of ROS, reduction of Nrf2 levels, and potent ability to 
synergize with DOX. 
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Employing affinity chromatography to purify whole-cell polyubiquitinated proteins, we 
discovered that RTI-79 increased the polyubiquitination state of several UPRmt proteins (Figure 
4.4; DNAJ[mtHSP40], HSP60, and mtHSP70[mortalin]) on lys48, a ubiquitin mark that targets 
proteins for proteasomal degradation (564). Velcade (a proteasome inhibitor) did not change the 
ubiquitination state of UPRmt proteins. Velcade does not exhibit the ability to potentiate 
Doxorubicin like RTI-79 and is cytotoxic to lymphoma cells on its own (Data are not shown). In 
addition, RTI-79 increased the polyubiquitination state of GrpE1, which controls the nucleotide-
dependent binding of mitochondrial HSP70 (mtHSP70 [mortalin]) to substrate proteins, and can 
stimulate its ATPase activity. GrpE1 also interacts with DNAJ [mtHSP40]. The expression 
levels of UPRmt chaperones was lower in RTI-79-chemosensitized cells relative to 
chemoresistant cells (Figure 4.4, in particular HSP40), indicating that increases in 
polyubiquitination was likely not the result of reduced proteasomal degradation activity. 
Moreover, one published report indicates that Nrf2 can upregulate HSP40 and mtHSP70 
expression (565). Thus, altered ubiquitination/stability of UPRmt proteins may be a mechanism 
driving chemoresistance in cancer cells.  
RTI-79 reduced phosphorylation (activity) of CREB at Ser133 (Figure 4.5). A potential 
mechanism would be modulation of Ca+2/calmodulin-dependent protein kinase II (CaMKII) or 
protein kinase A (PKA), which are known to target phosphorylation of Ser133 on CREB, which 
activates it to mediate nuclear gene expression. We hypothesize that UPRmt-mediated 
phosphorylation at Ser133 on CREB by CaMKII activates retrograde signaling, which 
upregulates Nrf2 and G6PDH. In support of this model, activation of CREB has been reported to 
induce the G6PDH gene (566, 567), as we detected Ca+2 fluxing about 5-10 minutes after the 
initial ROS burst in RTI-79-treated cells (Figure 4.6), which might activate CaMKII to 
phosphorylate CREB. Once activated by CaMKII-mediated phosphorylation at Ser133, CREB 
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could then activate transcription of the Nrf2 gene indirectly through activation of the PGC-1 
transcription factor (568). Nrf2 would then activate transcription of the G6PDH gene (442) thus 
increasing NADPH via the pentose phosphate shunt, which is used to increase GSH production. 
In support of this model, the G6PDH gene promoter has an antioxidant response element and the 
Keap1/Nrf2 system stimulates G6PDH transcription under stressed conditions (444). Moreover, 
we showed increased Nrf2, G6PDH, NADPH, and GSH in chemoresistant cells (chapter II), and 
RTI-79 decreased Nrf2, G6PDH, NADPH, and GSH in chemoresistant cells to levels more 










Figure 4.4 Drug-resistant cancer cells have higher UPRmt proteins than their more 
 
                   sensitive counterparts. (Panel A) Drug-resistant G3 lymphoma cells had higher 
UPRmt proteins than their more sensitive 2631 counterparts. RTI-79 caused decreases in UPRmt 
expression in G3 cells. (Panel B) RTI-79 also increased polyubiquitination in doxorubicin-




Figure 4.5 RTI-79 decreases CREB phosphorylation in G3 cells. RTI-79 decreased CREB 
phosphorylation at Ser133 indicating inactivation of CREB in drug-resistant G3 lymphoma cells. 








Figure 4.6 RTI-79 increases Ca+2 fluxing after the initial ROS burst. The rate of ROS and 




Figure 4.7 RTI-79 downregulates the Nrf2/G6PDH cascade in chemoresistant cells. (A) 
RTI-79 reduced NADPH levels in drug-resistant G3 lymphoma cells to that observed in the more 
sensitive 2631 line. (B) 10 µM RTI-79 decreased GSH levels in drug-resistant G3 levels to 
similar levels observed in their more sensitive counterparts after 12 hours of exposure. (C) 





4.4 Characterize UPRmt ubiquitin-conjugating enzymes in chemoresistant and RTI-79-
chemosensitized cells. 
The polyubiquitination at lysine 48 is a tag for the proteasome pathway, one of the main 
processes of cellular protein degradation (569). In this respect, the ability of deubiquitinating 
enzymes (DUBs) to edit the ubiquitination state of a protein or to cleave polyubiquitin chains 
from substrates is a key step in the correct definition of tags for subcellular localization and 
intracellular trafficking of the target protein (570). The differences in ubiquitination in 
mitochondrial chaperones between chemosensitive and chemoresistant cells, as well as RTI-79-
induced changes in ubiquitination, occur on lysine 48, indicating changes in the degradative 
proteasomal signal.  
Mitochondrial-specific E3 ubiquitin ligases (MITOL, GIDE, RNF185, and Parkin) (571-574) 
and deubiquitylases (DUBs; USP30 and USP35) (575) are known to regulate mitochondrial 
function through the UPRmt. We thus plan to identify and characterize ubiquitin-conjugating 
enzymes in mitochondria of chemosensitive, chemoresistant, and RTI-79-treated lymphoma and 
ovarian cells. The goals are to (1) identify an ubiquitin-conjugating modifier that is differentially 
expressed/activated in chemosensitive and chemoresistant cells, and (2) identify a specific 
ubiquitin-conjugating modifier in chemoresistant cells that we believe is targeted by RTI-79. The 
next approach will be to modulate this ubiquitin-conjugating modifier to confirm its role in 
chemoresistance. Initial studies will employ our chemosensitive/chemoresistant cell line models 
(CRL2631/G3 – diffuse large B-cell lymphoma; OVCAR8/ADR-RES – ovarian carcinoma) 
(82). Follow-up studies will be expanded to include other chemosensitive/chemoresistant 
lymphoma and ovarian carcinoma cell line pairs that we have generated in the laboratory. 
Western blotting of purified mitochondria lysates using an anti-ubiquitin antibody detected 
markedly increased polyubiquitination of proteins in RTI-79-treated chemoresistant lymphoma 
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cells compared to DMSO-treated controls (see arrow in Figure 4.8). Based on our preliminary 
studies, we believe this high molecular weight species is the result of increases in the 
polyubiquitination state of specific UPRmt proteins. We believe it is feasible to conduct 
characterization of ubiquitin-conjugating enzymes targeted by RTI-79 in an in vitro 
ubiquitination assay of purified whole-mitochondria. We hypothesize that the lower 
polyubiquitinated state of UPRmt chaperones in chemoresistant cells is caused by decreased E3 
ligase or increased deubiquitinase activity. RTI-79 targets a specific ubiquitin-conjugating 
modifier to increase the lys48 ubiquitination state of UPRmt chaperones, marking them for 
proteosomal degradation. 
Therefore, whole-mitochondria or mitochondrial lysates from chemosensitive, chemoresistant, 
and RTI-79-chemosensitized cells will be subjected to in vitro ubiquitination assays. Ubiquitin 
ligases and DUBs can be tagged in the in vitro assays with HA-ubiquitin and purified by affinity 
chromatography on anti-HA agarose or by the UBI-QAPTURE-Q® kit (Enzo Life Sciences). 
Eluted ubiquitinated proteins from chemoresistant and chemosensitized cells will be compared 
by mass spectrometry (MS). We will focus on differentially-expressed sequences using the same 
approach that successfully identified polyubiquitinated UPRmt chaperones in the Preliminary 
Data (Figure 4.4). However, this study will include a more expansive analysis of ubiquitin-
modified proteins ranging from mono- to poly-ubiquitination forms. 
De-ubiquitinating (DUB) activities will be assayed in whole-mitochondrial lysates subjected to 
ubiquitination reactions containing or lacking RTI-79 in the presence of biotin- or HA-ubiquitin, 
and the ubiquitinated proteins probed by western using avidin or anti-HA, respectively, as 
described (562, 563). If RTI-79 inhibits a DUB, then the level of HA-ubiquitination would be 




Figure 4.8 RTI-79 increases polyubiquitination of proteins in mitochondria lysates. G3 
lymphoma cells were treated with DMSO or RTI-79 (10 µM) for 4 hours. Mitochondria were 










If a DUB is involved in RTI-79-mediated chemosensitization, then we would expect to see 
increased amounts of biotin-ubiquitin tag in whole-mitochondrial proteins isolated from RTI-79-
chemosensitized cells treated with biotin-ubiquitin compared to control cells. These biotin-
ubiquitin-tagged candidates will be affinity-purified with avidin-conjugated agarose and 
subjected to MS sequencing for identification.  
Alternatively, we could purify ubiquitin-conjugating activities in mitochondrial lysates using 
classical hydrophobic, anion-exchange, and gel-filtration chromatography and an in vitro 
ubiquitination assay (Enzo Life Sciences, Inc.), which can tag E3 ligases and DUBs with HA-
ubiquitin or biotin-ubiquitin. We expect that an ubiquitin conjugation-modifying enzyme will be 
identified as differentially activated/regulated between drug-sensitive and –resistant cells. RTI-
79 will be shown to bind to the ubiquitin-conjugation modifier (E3 ligase or DUB) and modulate 
its activity. Downregulation (siRNA knockdown) or upregulation (recombinant lentivirus 
expression) of the candidate ubiquitin-conjugation modifier will influence the drug tolerance of 
chemoresistant and chemosensitive cells. Our studies will be expanded to include other paired 
chemosensitive/chemoresistant lymphoma and ovarian carcinoma cells available in the 
laboratory. Moreover, the effect of modulating the ubiquitin-conjugating modifier on CREB 
phosphorylation, Nrf2, and G6PDH/GSH will be investigated as described below under sections 
4.5 and 4.6.  
 
4.5 Modulate UPRmt chaperone expression and CREB (phosphoSer133) activity and 
determine the effect on chemoresistance. 
Here we hypothesize that activation or upregulation of the UPRmt activates CaMKII, which 
phosphorylates and activates CREB to transactivate the Nrf2 and G6PDH genes. The role of 
CREB signaling in chemoresistance and chemosensitization will be investigated using siRNA 
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knockdown and cell-permeable CREB inhibitors (Calbiochem; Santa Cruz). CaMKII activity 
will be modulated using siRNA, and chemical inhibitor (KN-93) and activator (Oleic acid, Santa 
Cruz; Tocris). PKA activity will be modulated using siRNA, and chemical inhibitor (H89, Santa 
Cruz) and activator (8-bromo-cAMP, Santa Cruz). UPRmt chaperone proteins will be modulated 
by siRNA knockdown (576), lentivirus overexpression (Vigene Biosciences, Inc), and induction 
by paraquat (577) or ethidium bromide-induced depletion of mtDNA (576), and the effect on 
CREB activity (Ser133 phosphorylation) will be determined. Ubiquitin-conjugating modifiers 
interacting with RTI-79 identified in section 4.4 will be modulated by siRNA and the effect on 
CaMKII, CREB, and chemoresistance determined. We would expect to see that inhibition of 
CREB or CaMKII will decrease tolerance to chemotherapeutics (doxorubicin. etoposide, 
cisplatin). Downregulation of UPRmt proteins (HSP40, HSP60, and mtHSP70), inhibition of 
CREB, and inhibition of CaMKII will result in decreases in both Nrf2 and G6PDH, decreases in 
both NADPH and GSH, and increases in ROS (oxidative state) expression, thereby sensitizing 
chemoresistant cells to chemotherapeutics. Upregulation of UPRmt proteins (by paraquat or 
recombinant lentivirus) or activation (phosphorylation at ser133) of CREB will have the opposite 
effect, increasing Nrf2/G6PDH and drug tolerance in drug-sensitive cells. However, if CREB is 
acting directly to regulate the G6PDH gene, then modulation of CREB may affect G6PDH but 
not Nrf2 expression. 
Alternatively, if CREB is ruled out, other molecules that mediate retrograde signaling will be 
investigated. For instance, UPRmt retrograde signaling is also mediated by the bZip transcription 
factor ATFS-1 (578), which is normally efficiently imported into mitochondria and degraded. 
The expression and localization of ATFS-1 by cell fractionation and western blot could be 
studied by using anti-ATFS-1 antibody (Biocompare, Inc.). If a role for ATFS-1 is eliminated, 
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we would examine still other transcription factors implicated in retrograde signaling, such as 
CHOP and NFκB (579). 
 
4.6 Determine the role of the Nrf2/G6PDH/GSH pathway in UPRmt-mediated drug 
resistance.  
Mitochondrial retrograde signaling activates the Nrf2/HO-1 cascade during oxidative stress 
(580-582). Thus, constitutive activation of UPRmt might promote stabilization, and thus 
upregulation, of Nrf2, which then upregulates G6PDH. Nrf2 is anchored in the cytoplasm 
through binding to Keap1, which, in turn, facilitates the ubiquitination and subsequent 
proteolysis of Nrf2. Such sequestration and degradation of Nrf2 in the cytoplasm is a mechanism 
for the repressive effects of Keap1 on Nrf2. We suspect that RTI-79 downgrades UPRmt 
retrograde signaling, resulting in destabilization and downregulation of Nrf2 protein since 
increases in cytoplasmic Nrf2 relative to nuclear Nrf2 protein were observed in RTI-79-treated 
cells (Figure 4.9). We thus will investigate whether either UPRmt or RTI-79 alone modulates 
Nrf2-Keap1 interactions. 
Here we hypothesize that UPRmt activates retrograde signaling, which stabilizes Nrf2 and 
upregulates G6PDH, thus lowering the oxidative state and increasing tolerance to 
chemotherapeutics. Therefore we plan to modulate the expression of UPRmt chaperones to 
influence the Nrf2/G6PDH/GSH cascade and chemoresistance. 
Overexpression of an aggregation-prone mutant mitochondrial protein, ornithine 
transcarbamylase (ΔOTC), results in UPRmt activation and efficient clearance of misfolded 
ΔOTC (538). Chemosensitive CRL2631 lymphoma and OVCAR8 ovarian carcinoma cells will 
be transfected with recombinant ΔOTC to activate the UPRmt. Alternatively, the UPRmt can be 
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upregulated by paraquat. The effect of upregulation of UPRmt on chemosensitivity will be 
investigated along with the determination of CREB, Nrf2, and G6PDH activities and ROS levels. 
Also, Keap1/Nrf2 interactions and Nrf2 activity will be determined using three independent 
assays: (1) PathHunter NRF2 assay (DiscoverRX, Inc), (2) Keap1/Nrf2 Screening Assay Kit 
designed for study of Keap1/Nrf2 binding (BPS Bioscience, Inc), and (3) Antioxidant Response 
Reporter System (ARRS; Qiagen). The effect of knocking down UPRmt retrograde signaling 
(described in section 4.4) (HSP40, mtHSP70, and HSP60 siRNAs) on Keap/Nrf2 interactions 
will be investigated in drug-sensitive and -resistant cells. If we do not see changes in Nrf2/Keap 
interactions, we could explore other pathways of Nrf2 activation. Nrf2 activity is regulated by 
not only Keap-mediated ubiquitination as described above but also phosphorylation of serine 
residues in the Nrf2 protein (583, 584). Several kinases reportedly phosphorylate Nrf2 at Ser40, 
and Nrf2 is a direct substrate of PERK, a kinase that acts as a transducer of ER stress (585). We 
would investigate both nuclear/cytoplasmic localization of Nrf2 and its state of phosphorylation 
and ubiquitination. 
G6PDH activity and NADPH will be modulated in both drug-sensitive and -resistant cells using 
chemical G6PDH inhibitor DHEA and recombinant lentiviruses expressing G6PDH protein or 
shRNA. GSH levels in both drug-sensitive and resistant cells will be modulated using inhibitors 
of GSH synthesis (L-buthionine sulfoximine; the glutathione reductase inhibitor 2-AAPA) and 
GSH activator (Riluzole). Glutathione Monoethyl Ester (Santa Cruz, Inc) is a cell-permeable 
derivative of glutathione (GSH) that undergoes hydrolysis by intracellular esterases to release 
GSH. We already have a preliminary result showing that the GSH inhibitor, L-buthionine 
sulfoximine, sensitized chemoresistant lymphoma cells to doxorubicin. G6PDH activity and 
GSH levels will be determined using fluorescent- and colorimetric-based assays, respectively 
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(Figures 4.10 and 4.7B). The effect of UPRmt knockdown (siRNA) and upregulation 
(recombinant lentivirus) on G6PDH activity and GSH levels will be determined as we have done 
in the Preliminary Results. 
We anticipate that upregulation of G6PDH will increase the levels of GSH and lower ROS, thus 
increasing the tolerance of drug-sensitive cells to chemotherapeutics. Upregulation of UPRmt 
will increase G6PDH activity and GSH, increase chemoresistance, and lower ROS. 
Downregulation of UPRmt will decrease G6PDH activity and GSH, reverse chemoresistance, 












Figure 4.9 RTI-79 increases cytoplasmic Nrf2 relative to nuclear Nrf2. RTI-79 repressed 
doxorubicin-induced increases in Nrf2 localization with concomitant increases in the proportion 





Figure 4.10 RTI-79 decreases the G6PDH activity in G3 cells. RTI-79 caused a dose-
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